US20040236211A1 - Marker or filler forming fluid - Google Patents

Marker or filler forming fluid Download PDF

Info

Publication number
US20040236211A1
US20040236211A1 US10/444,428 US44442803A US2004236211A1 US 20040236211 A1 US20040236211 A1 US 20040236211A1 US 44442803 A US44442803 A US 44442803A US 2004236211 A1 US2004236211 A1 US 2004236211A1
Authority
US
United States
Prior art keywords
marker
mass
fluid
poly
biocompatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/444,428
Other versions
US7877133B2 (en
Inventor
Fred Burbank
Michael Jones
Frank Louw
Paul Lubock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SenoRx Inc
Original Assignee
SenoRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/444,428 priority Critical patent/US7877133B2/en
Application filed by SenoRx Inc filed Critical SenoRx Inc
Assigned to SENORX, INC. reassignment SENORX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BURBANK, FRED H., JONES, MICHAEL L., LOUW, FRANK, LUBOCK, PAUL
Priority to PCT/US2004/014731 priority patent/WO2004105803A1/en
Publication of US20040236211A1 publication Critical patent/US20040236211A1/en
Priority to US12/214,947 priority patent/US10299881B2/en
Priority to US12/967,639 priority patent/US8447386B2/en
Publication of US7877133B2 publication Critical patent/US7877133B2/en
Application granted granted Critical
Priority to US13/895,927 priority patent/US8639315B2/en
Priority to US14/143,738 priority patent/US10045832B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3904Markers, e.g. radio-opaque or breast lesions markers specially adapted for marking specified tissue
    • A61B2090/3908Soft tissue, e.g. breast tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3925Markers, e.g. radio-opaque or breast lesions markers ultrasonic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3933Liquid markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3987Applicators for implanting markers

Definitions

  • This invention relates generally to the introduction of filler or marker material into a patient's body, and particularly to the filling a biopsy site within a patient's body from which a biopsy specimen has been taken with a mass of marker material.
  • a biopsy In diagnosing and treating certain medical conditions, it is often desirable to perform a biopsy, in which a specimen or sample of tissue is removed for pathological examination, tests and analysis.
  • obtaining a tissue sample by biopsy and the subsequent examination are typically employed in the diagnosis of cancers and other malignant tumors, or to confirm that a suspected lesion or tumor is not malignant.
  • the information obtained from these diagnostic tests and/or examinations is frequently used to devise a plan for the appropriate surgical procedure or other course of treatment.
  • breast biopsies may be taken where a suspicious lump or swelling is noticed in a breast. Examination of tissue samples taken by biopsy is of particular significance in the diagnosis and treatment of breast cancer.
  • the biopsy and treatment site described will generally be the human breast, although the invention is suitable for marking biopsy sites in other parts of the human and other mammalian body as well.
  • biopsy site markers including visible markers applied externally to the patient's skin, radiographically (X-ray)-detectable tissue markers such as clips and staples, and ultrasound-detectable markers, have also been described.
  • X-ray-detectable marker wires may be inserted through a biopsy needle, leading from the surface of the patient's body to the biopsy site. Some markers may be biodegradable.
  • biopsy site markers may not remain at the specific biopsy location after the breast has been decompressed and removed from the mammography apparatus, and may suffer from additional disadvantages as well.
  • an additional mammography is generally required at the time of follow up treatment or surgery.
  • the biopsy site must usually be marked again with a location wire that is visible by eye to provide guidance to the clinician performing the treatment or surgery.
  • the position of the location wire can change or shift before the treatment or surgery is performed, which may result in treatments being misdirected to undesired locations.
  • at least some prior art biopsy site markers can remain present at the site of implantation for an indefinite period of time and, if not surgically removed, may obscure or otherwise interfere with any subsequent mammography or imaging studies.
  • USI ultrasonic imaging and visualization techniques
  • USI can be used to image the tissue of interest at the site of interest during a surgical or biopsy procedure or follow-up procedure.
  • USI is capable of providing precise location and imaging of suspicious tissue, surrounding tissue and biopsy instruments within the patient's body during a procedure. Such imaging facilitates accurate and controllable removal or sampling of the suspicious tissue so as to minimize trauma to surrounding healthy tissue.
  • the biopsy device is often imaged with USI while the device is being inserted into the patient's breast and activated to remove a sample of suspicious breast tissue.
  • USI is often used to image tissue during follow-up treatment, it may be desirable to have a marker, similar to the radiographic markers discussed above, which can be placed in a patient's body at the site of a surgical procedure and which are visible using USI.
  • radiopaque markers may not be visible with USI.
  • a marker visible with USI enables a follow-up procedure to be performed without the need for traditional radiographic mammography imaging which, as discussed above, can be subject to inaccuracies as a result of shifting of the location wire as well as being tedious and uncomfortable for the patient.
  • biopsy site markers that are deliverable into the cavity created by removal of the biopsy specimen and not into tissue that is located outside of that biopsy cavity, and which will not migrate from the biopsy cavity even when the breast tissue is moved, manipulated or decompressed.
  • desired markers should remain detectable at the biopsy site (i.e., within the biopsy cavity for a desired time period); should not interfere with imaging of the biopsy site and adjacent tissues at a later time; and should be readily distinguishable in the various imaging procedures from lines of calcifications which frequently are signs for a developing malignancy.
  • the invention is directed to the deployment of a marker or filler forming material at intracorporeal locations such as biopsy sites, sites for cosmetic treatments and other sites which may need additional bulk.
  • the marker or filler material is formed intracorporeally from a biocompatible solution having as a solute bioabsorbable polymeric material which is relatively insoluble in body fluid or other water based fluids and a water soluble, non-aqueous polar solvent such as dimethyl sulfoxide (DMSO).
  • Suitable bioaborbable polymers include polylactic acid, polyglycolic acid, polycaprolactones and copolymers and blends thereof.
  • the non-aqueous solvent is quickly absorbed by the body fluid or water based fluid present at the site, precipitating a mass of the water insoluble bioabsorbable polymeric material at the site.
  • the polymeric material forming the marker or filler mass is preferably inherently ultrasonically detectable or the marker fluid may be treated to have a plurality of gas bubbles or otherwise aerated, so that upon formation of the polymeric mass at the site, gas is incorporated in the solid mass forming to provide ultrasonically detectable porosity.
  • a guiding member such as a cannula or other tubular member is preferably left within the patient with the distal end thereof within or close to the biopsy site in order to provide subsequent access to the biopsy site.
  • the tubular guiding member may be part of the biopsy system such as a SenoCor 360TM or a Mammotome® system which was used to separate the tissue specimen and remove it from the site but which remains in place after the specimen has been removed.
  • the marker forming fluid embodying features of the invention may be suitably delivered by a syringe with an elongated delivery tube which at least in part fits within a tubular guiding member leading to the biopsy site.
  • the amount of polymeric solute ranges from about 1 to about 50%, preferably about 10 to about 35% by weight of the marker or filler forming fluid.
  • the ratio of the polymer solute to the solvent can be varied to adjust the delivery characteristics and the in-vivo lifetime (i.e. the time period in which the polymeric mass is at the biopsy site). For example a lower percentage of polymeric material in the mix will provide a softer or more friable marker mass within the cavity, whereas a higher percentage will provide a firmer marker mass. Lower percentages of solvent will provide thicker marker fluids which will not be readily displaced from the biopsy site, whereas higher percentages will provide a less viscous solution which is easier to deliver.
  • High molecular weight polylactic acid provides a longer in-vivo life time, e.g. up to a year or more.
  • a lower molecular weight polymeric material such as a copolymer of lactic acid (90%) and glycolic acid (10%) provides an in-vivo life time of about two to three weeks.
  • a copolymer of lactic acid (65%) and glycolic acid (35%) with a molecular weight of about 60 kD has an in-vivo lifetime of about 12 to 14 weeks.
  • an ultrasound-detectable marker typically must remain in place and be remotely detectable within a patient for at least 2 weeks to have any practical clinical value.
  • an ultrasound-detectable marker material embodying features of the invention is detectable at a biopsy site within a patient for a time period of at least 2 weeks, preferably at least about 6 weeks, and may remain detectable for a time period of up to about 20 weeks or more.
  • An ultrasound-detectable marker mass embodying features of the invention is preferably not detectable after about one year, and usually not more than about 6 months after placement at a biopsy site. More preferably, the ultrasound-detectable marker mass should not be detectable with ultrasound after about 12 weeks from placement at a biopsy site.
  • a preferable in-vivo lifetime for an ultrasound-detectable biopsy marker mass having features of the invention is about 6 weeks to about 12 weeks.
  • the detectable marker mass which forms in the biopsy cavity should be large enough to fill a substantial portion, preferably all of the cavity. This allows the detection and definition of the boundaries of the biopsy cavity.
  • the accessing passageway leading to the biopsy cavity may also at least in part be filled with the marker fluid as well if desired, which allows the physician to follow to locate the marker mass.
  • the marker mass which forms in the cavity is ultrasonically detectable, but the marker fluid may also include ultrasonically or radiographically detectable powders or other particulate to augment the detection of the polymeric mass or the biopsy cavity.
  • therapeutic and diagnostic agents may be incorporated into the marker fluid such as pharmaceutical agents, chemotherapeutic agents, anesthetic agents, hemostatic agents, pigments, dyes, radiopaque agents, materials detectable by magnetic resonance imaging (MRI), inert materials, and other compounds.
  • pharmaceutical agents chemotherapeutic agents, anesthetic agents, hemostatic agents, pigments, dyes, radiopaque agents, materials detectable by magnetic resonance imaging (MRI), inert materials, and other compounds.
  • the delivery system is employed to incorporate a radiopaque or other type of long term or permanent marker element within the polymeric mass which forms in the biopsy cavity.
  • the distal end of the syringe assembly or the tubular guide member leading to the biopsy site may be provided with a distal tip which is formed of radiopaque or other suitable material and which is releasably secured to the distal portion of the syringe or guide member so that upon formation of the marker mass from the marker fluid, the distal tip of the syringe or guide member can be released within the formed polymer marker mass and the syringe or guide member then removed from the mass.
  • the biopsy site markers formed by the present invention provide ultrasonically bright images which can be readily distinguished from the ultrasound signals arising naturally from within a breast or other tissue and which readily contrasts with the dark ultrasound shadow region immediately behind the bright ultrasound echo region.
  • the strength of the reflected signal, and the contrast with the shadow region make the marked site readily detectable even to relatively inexperienced surgeons.
  • the in-vivo lifetime of the marker at the biopsy site can be preselected by adjusting the amount of polymeric material in the marker fluid and the molecular weight thereof.
  • the employment of the filler forming functions of the solution may be advantageously utilized in cosmetic treatments similar to the uses of collagen, e.g. wrinkle removal or minimization, or in situations in which additional bulk is needed within a patient's body, e.g., treating for urinary incontinence.
  • FIG. 1A is an elevational view, partially in section, of a marker fluid delivery system embodying features of the invention.
  • FIG. 1B is a transverse cross-sectional view taken along line 1 B- 1 B shown in FIG. 1A.
  • FIG. 1C is a transverse cross-sectional view taken along line 1 C- 1 C shown in FIG. 1A.
  • FIG. 1D is a transverse cross-sectional view taken along line 1 D- 1 D shown in FIG. 1A.
  • FIG. 2 is a partially cut-away, perspective view of a system as illustrated in FIG. 1 shown depositing a marker fluid embodying features of the invention at a biopsy site within a breast of a female patient.
  • FIG. 3 is a perspective view, partially in section, of the distal portion of a delivery system having a releasable marker element on the distal tip of the delivery tube which acts as a long term or permanent marker.
  • FIG. 4 is a longitudinal, centerline cross-section of a delivery system having a releasable radiopaque distal tip.
  • FIG. 5 is a longitudinal, centerline cross-section of a delivery system having a releasable radiopaque distal tip which is threadably connected to the distal end of the delivery cannula and which has a grooved exterior to facilitate release of the distal tip.
  • FIG. 6 is a transverse cross-sectional view of the releasable distal tip shown in FIG. 5 taken along the lines 6 - 6 .
  • FIG. 7 is an elevational view of a delivery cannula suitable for use to deliver the marker or filler forming fluid embodying features of the invention.
  • FIGS. 1A-1D illustrate a system 10 for delivery of biopsy marker fluid 11 embodying features of the invention to a biopsy site within a patient's body.
  • the system 10 includes a syringe 12 having a bore 13 containing a quantity of biopsy marker fluid 11 .
  • a plunger 14 with a sealable distal end 15 is slidably disposed within the bore 13 of syringe 12 .
  • Application of pressure to the head 16 of plunger 14 applies pressure to the fluid 11 and causes the discharge of fluid 11 from the bore 13 into the inner lumen 17 of delivery tube 18 secured to the discharge end of syringe 12 .
  • the marker fluid 11 passes through the inner lumen or bore 17 of the delivery tube 18 and out the discharge port 19 in the distal end of delivery tube 18 .
  • delivery tube 18 is secured to the syringe 12 by a friction fit.
  • the delivery tube 18 may have markings, such as lines or dots spaced at regular intervals along the length of the tube to indicate its position within the patient.
  • FIG. 2 illustrates the marker fluid delivery system 10 shown in FIGS. 1A-1D with the distal portion of the delivery tube 18 operatively disposed within a patient's breast 20 with the distal tip 21 of the delivery tube 18 disposed within biopsy cavity 22 at the biopsy site 23 ready to deliver marker fluid 11 .
  • An incision 24 in the breast 20 allows access to the cavity 22 .
  • Biopsy tubular guide member 25 extends through incision 24 in the patient's breast 20 into cavity 22 at biopsy site 23 .
  • the distal end 26 of syringe 12 containing marker fluid 11 , is tightly engaged with delivery tube 18 , which extends within guide member 25 so as to locate delivery tube outlet port 19 within biopsy cavity 22 .
  • the outer diameter of the delivery tube 18 is configured to allow the delivery tube to slidably fit inside the inner lumen 27 of biopsy guide member 25 .
  • Markings 28 spaced at regular intervals along the outer surface of delivery tube 18 indicate the depth of insertion of the tube within the guide member 25 and aid in the proper placement of discharge port 19 into position within cavity 22 .
  • Depression of plunger 14 of the syringe 12 forces marker fluid 11 out of syringe 12 through the inner lumen 17 of the delivery tube 18 and out port 19 into the cavity 22 .
  • Fluid 11 mixes with body fluid or other water based fluid which may be present in the cavity 22 .
  • the solvent in fluid 11 is quickly dissolved in the body fluid or other water based fluid.
  • the polymer solute which precipitates is relatively insoluble in the body fluid or other water based fluid which may be present in the cavity and forms a porous, ultrasonically detectable and bioabsorbable polymer mass 30 within the cavity 22 .
  • the mass 30 preferably essentially fills the biopsy cavity 22 so as to define the periphery of the biopsy cavity and to ensure that the mass remains within the biopsy cavity and will not migrate.
  • the mass is subsequently absorbed by tissue and fluids near the biopsy site, so that at the end of the in-vivo life time of the bioabsorbable mass 30 , the marker mass is no longer readily detectable at the site by ultrasonic means. Tissue ingrowth usually replaces the absorbed mass.
  • the preferred solvent for the fluid 11 is a pharmaceutical grade (USP) of DSMO.
  • USP pharmaceutical grade
  • Other biocompatible water soluble, polar solvents are suitable.
  • the preferred relatively water-insoluble bioabsorbable polymers are polylactic acid, poly glycolic acid, copolymers of lactic acid and glycolic acid, polycaprolactone.
  • bioabsorbable, essentially water insoluble polymers include poly(esters), poly(hydroxy acids), poly(lactones), poly(amides), poly(ester-amides), poly(amino acids), poly(anhydrides), poly(ortho-esters), poly(carbonates), poly(phosphazines), poly(thioesters), poly(urethanes), poly(ester urethanes), polysaccharides, polylactic acid, polyglycolic acid, polycaproic acid, polybutyric acid, polyvaleric acid, and copolymers, polymer alloys, polymer mixtures, and combinations thereof.
  • the marker mass preferably essentially fills the biopsy cavity so as to define the periphery of the biopsy site cavity and to ensure that the marker mass remains within the biopsy cavity and will not migrate.
  • the marker materials are resorbed by tissue and fluids near the biopsy site, so that, after their in-vivo life times, the marker materials are no longer USI-detectable at the biopsy site.
  • the marker fluid may also include radiopaque materials or radiopaque markers, so that the biopsy site may be detected both with ultrasound and with X-ray or other radiographic imaging techniques.
  • Radiopaque materials and markers may include metal objects such as clips, bands, strips, coils, and other objects made from radiopaque metals and metal alloys, and may also include powders or particulate masses of radiopaque materials.
  • Radiopaque markers may include liquid contrast agents such as Ethiodol or other non-water based contrast agents. Radiopaque markers may be of any suitable shape or size, and are typically formed in a recognizable shape not naturally found within a patient's body.
  • Suitable radiopaque materials include stainless steel, platinum, gold, iridium, tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys and oxides of these metals, barium salts, iodine salts, iodinated materials, and combinations of these.
  • the marker fluid may also include MRI-detectable materials or markers, so that the biopsy site may be detected with MRI techniques.
  • MRI contrast agents such as gadolinium and gadolinium compounds, for example, are suitable for use with ultrasound-detectable biopsy marker materials embodying features of the invention.
  • Colorants such as dyes (e.g., methylene blue and carbon black) and pigments (e.g., barium sulfate), may also be included in the marker fluid of the invention.
  • the colorant such as carbon black usually remains in the track or passageway leading to the marker or filler mass and this can be followed by the surgeon to the desired location.
  • Therapeutic agents to reduce bleeding, enhance clotting, to cause vasoconstriction, to prevent infections and other diseases, to reduce pain, chemotherapeutic agents to treat remnant cancer cells at the site may be incorporated into the marker fluid. Suitable therapeutic agents are provided in co-pending application Ser. No. 10/1214,757, filed on Jul. 27, 2002, which is incorporated herein in its entirety by reference.
  • FIGS. 3 and 4 depict the distal portion of an alternative delivery tube 30 which is disposed within tubular guide 31 and which has a releasable radiopaque element 32 on the distal tip of the delivery tube.
  • a cannula 33 is slidably disposed about the delivery tube 30 . Relative longitudinal movement between the cannula 33 and delivery tube 30 , as depicted by arrows 34 and 35 , pushes the radiopaque element 32 off the end of the tube into the cavity 36 as shown in FIG. 4.
  • the radiopaque element 32 is released from the delivery tube 30 and left within the polymer mass.
  • the radiopaque element 32 is released within the polymer mass at a point in the formation of the mass which ensures that the position of the radiopaque element 32 is maintained after the distal end of the delivery tube 30 is removed from the cavity 36 .
  • the radiopaque element 32 is centrally located within the biopsy cavity 36 .
  • FIGS. 5 and 6 illustrate an alternative embodiment in which a releasable radiopaque element 40 is the distal tip of delivery tube 41 .
  • the element 40 is threadably connected to the distal portion of the delivery tube 41 and has a grooved exterior 42 which helps to fix the tip in the polymeric mass. This allows the delivery tube 41 to be unscrewed from the tip element 40 and to be withdrawn from the patient, leaving the radiopaque tip 40 within the polymeric mass.
  • the releasable radiopaque element may have a variety of other shapes which are recognizable as not being naturally found within a patient's body to facilitate remote detection radiographically or ultrasonically.
  • the radiopaque may have an exterior transverse shape such as a star or a square.
  • the radiographically detectable distal tip may be formed of a suitable radiopaque material such as stainless steel, platinum, gold, iridium, tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys and oxides of these metals.
  • Radiopaque salts such as barium salts, iodine salts, iodinated materials, and combinations of these may be incorporated into polymeric or ceramic materials which form the releasable tip.
  • the deployment system may have a delivery tube 50 with a needle-like distal tip 51 to facilitate advancement of the delivery tube through tissue to the target site.
  • This embodiment is particularly suitable in those situations in which there is no guide tube or other cannula in place to provide access to the target site.
  • Markers embodying features of the present invention remain detectable at an intracorporeal site for a desired time period, and degrade or dissolve so as to not interfere with imaging of the biopsy site and adjacent tissues at a later time. Suitable marker materials typically do not migrate from the biopsy site before being dissolved or otherwise absorbed, and so provide reliable temporary marking of the location of a biopsy site and the margins thereof.
  • the marker materials having features of the invention are readily distinguishable from natural body features including signs of a developing or an actual malignancy.
  • the present invention also includes apparatus and method for delivering markers to a biopsy site.
  • the purpose of markers embodying features of the invention is to facilitate the location and performance of a surgical procedure that is performed while the marker is still detectable.
  • the in-vivo lifetime of the marker mass remaining in the biopsy cavity is relatively short, e.g. less than one year, preferably less than about six months.
  • the marker mass should have an in-vivo life time of about 6 to about 20 weeks, preferably 6 to 12 weeks. The disappearance of a marker after a longer period of time is required to avoid obscuring or interfering with follow-up imaging or further mammography.
  • the marker fluid embodying features of the present invention containing ultrasound-detectable solute of bioabsorbable polymeric material of the present invention is deposited at a biopsy site within a patient's body to form a biopsy marker mass at the site to allow for the subsequent location of the site by medical personnel.
  • a quantity of fluid formed of a non-aqueous water soluble solvent such as DSMO with a bioabsorbable polymeric material which is essentially insoluble in body fluids or other water based fluids is delivered into a cavity at a biopsy site.
  • the solvent is quickly dissolved in the body fluid and the relatively water insoluble polymeric solute forms a marker mass within the biopsy cavity.
  • the in-vivo lifetime of the polymeric material i.e. the time period in which the polymeric mass is ultrasonically detectable, is related to the molecular weight of the polymer.
  • copolymers of lactic and glycolic acids having an initial molecular weight of about 45,000 Daltons (45 kD) before processing are suitable for use in making an ultrasound-detectable marker material having an in-vivo lifetime of about 12 weeks.
  • other materials, including other polymeric materials may require a different starting molecular weight in order to obtain the same in-vivo lifetime.
  • polyglycolic acid typically degrades faster than other materials and as such requires a substantially higher initial molecular weight than polylactic acid or polycaprolactone to obtain a similar in-vivo lifetime.
  • Many properties of a material affects the intensity of its ultrasound reflection, including density, physical structure, molecular material, and shape. For example, sharp edges, or multiple reflecting surfaces on or within an object differing in density from its surroundings enhances its ability to be detected by ultrasound. Interfaces separating materials of different densities, such as between a solid and a gas, produce strong ultrasound signals.
  • the methods of the present invention provide materials having a porosity effective to produce strong ultrasound signals when located within the patient's biopsy cavity.
  • the polymeric material may naturally form a porous mass or porosity can be formed by introducing a gas into the material during processing of a material, by release of gas from within the material, or by directing a gas into a material or by incorporating a blowing agent.
  • a typical human breast has a substantial number of features that are visualized with ultrasound. These features all have characteristic signals. Fibrous tissue or ligaments tend to show up as bright streaks, fat seems to appear as a dark gray area, the glandular tissue appears as a mottled medium gray mass. Cancerous lesions typically appear as a darker area with a rough outer edge which has reduced through transmission of the ultrasound energy.
  • One advantage of the ultrasound-detectable biopsy marker materials of the present invention is that the materials provide an ultrasound signal which can be readily differentiated from anatomic structures within the breast, so that the identification and marking of a biopsy cavity does not require extensive training and experience.
  • the delivery syringe and the delivery tube attached to the syringe may be sized to accept any volume of marker or filler forming fluid desired to be injected into the desired intracorporeal site.
  • the average Mammotome® biopsy removes about 0.5 to about 2, typically about 1 ml of tissue.
  • the volume of marker fluid introduced into the biopsy cavity which remains after the removal of the tissue specimen is about the same as the tissue volume removed. Use of more marker fluid typically leads to some filling of the accessing passageway as well as of the cavity at the biopsy site. Smaller volumes of marker fluid may be used for smaller cavities at a biopsy site, such as are created with a single SenoCor 360TM biopsy or an automated Tru-Cute® biopsy.
  • the solution embodying features of the invention may also be employed as a filler or bulking agent.
  • the filler forming fluid may be used in a manner similar to collagen for cosmetic purposes to minimize wrinkles, to fill pockmarks and other surface pits.
  • the solution may also be used to bulk up an area of tissue for a variety of reasons. For example, if a radiation source for treating a tumor or a tumor site after removal of the tumor is located too close to the patient's skin, e.g. less than about 5 mm, the skin may be damaged or ultimately scarred by the irradiation.
  • the filler forming fluid embodying features of the invention between the irradiation source and the skin, the damage or scarring to the skin can be reduced or eliminated.
  • either a single bolus or multiple bolus may be employed to bulk up the region and to displace the skin sufficiently to avoid damage.
  • the filler forming fluid embodying features of the invention may also be employed to provide a bulking mass about a urethra in the treatment of urinary incontinence, for a bulking mass about an anal sphincter for fecal incontinence and a bulking mass about an esophageal sphincter for gastroesophageal reflux disease.
  • Other uses will become apparent to those skilled in the art.

Abstract

A solution for forming a marker or filler mass for an intracorporeal site. The solution contains a polar, water soluble non-aqueous solvent such as dimethyl sulfoxide and a bioabsorbable, essentially water insoluble polymer such as polylactic acid, or copolymers of lactic acid and glycolic acid. The solution may be delivered to the biopsy site by a suitable syringe and delivery tube. The delivery tube is preferably provided with a releasable radiopaque element on the distal tip which can be released within the polymeric marker mass formed in the biopsy cavity.

Description

    FIELD OF THE INVENTION
  • This invention relates generally to the introduction of filler or marker material into a patient's body, and particularly to the filling a biopsy site within a patient's body from which a biopsy specimen has been taken with a mass of marker material. [0001]
  • BACKGROUND OF THE INVENTION
  • In diagnosing and treating certain medical conditions, it is often desirable to perform a biopsy, in which a specimen or sample of tissue is removed for pathological examination, tests and analysis. As is known, obtaining a tissue sample by biopsy and the subsequent examination are typically employed in the diagnosis of cancers and other malignant tumors, or to confirm that a suspected lesion or tumor is not malignant. The information obtained from these diagnostic tests and/or examinations is frequently used to devise a plan for the appropriate surgical procedure or other course of treatment. For example, breast biopsies may be taken where a suspicious lump or swelling is noticed in a breast. Examination of tissue samples taken by biopsy is of particular significance in the diagnosis and treatment of breast cancer. In the ensuing discussion, the biopsy and treatment site described will generally be the human breast, although the invention is suitable for marking biopsy sites in other parts of the human and other mammalian body as well. [0002]
  • After the biopsy sample is taken, it may take several days or weeks before the results of the examination of the sample are obtained, and still longer before an appropriate treatment decision is reached. If the decision involves surgery it is clearly important for the surgeon to find the location in the breast from where the tumor tissue has been taken in the biopsy procedure, so that the entire tumor and possibly surrounding healthy tissue can be removed. [0003]
  • However, radiographically visible tissue features, originally observed in a mammogram, may be removed, altered or obscured by the biopsy procedure. In order for the surgeon or radiation oncologist to direct surgical or radiation treatment to the precise location of the breast lesion several days or weeks after the biopsy procedure was performed, it is desirable that a biopsy site marker be placed in or on the patient's body to serve as a landmark for subsequent location of the lesion. [0004]
  • Various types of biopsy site markers have been described, including visible markers applied externally to the patient's skin, radiographically (X-ray)-detectable tissue markers such as clips and staples, and ultrasound-detectable markers, have also been described. X-ray-detectable marker wires may be inserted through a biopsy needle, leading from the surface of the patient's body to the biopsy site. Some markers may be biodegradable. [0005]
  • However, due to the consistency of breast tissue and the fact that these biopsy site markers are typically introduced while the breast is still compressed between the mammography plates, prior art biopsy markers may not remain at the specific biopsy location after the breast has been decompressed and removed from the mammography apparatus, and may suffer from additional disadvantages as well. In order to locate an X-ray-detectable marker left at a biopsy site, an additional mammography is generally required at the time of follow up treatment or surgery. In addition, once it is located using mammography, the biopsy site must usually be marked again with a location wire that is visible by eye to provide guidance to the clinician performing the treatment or surgery. However, as the patient is removed from the mammography apparatus, or otherwise transported, the position of the location wire can change or shift before the treatment or surgery is performed, which may result in treatments being misdirected to undesired locations. Furthermore, at least some prior art biopsy site markers can remain present at the site of implantation for an indefinite period of time and, if not surgically removed, may obscure or otherwise interfere with any subsequent mammography or imaging studies. [0006]
  • However, due to the large amount of fibrous tissue normally present in a human breast, and due to the presence of ligaments running through the breast, a marker that simply has a bright signal alone will not provide a useful signal that is readily discernable from the many anatomic features normally present within a human breast. Such markers are typically small, being sized to fit within a syringe or other delivery tube, and so are often not readily distinguishable from natural features of the breast, which include occasional small ultrasound-bright spots. [0007]
  • As an alternative or adjunct to radiographic imaging, ultrasonic imaging and visualization techniques (abbreviated as “USI”) can be used to image the tissue of interest at the site of interest during a surgical or biopsy procedure or follow-up procedure. USI is capable of providing precise location and imaging of suspicious tissue, surrounding tissue and biopsy instruments within the patient's body during a procedure. Such imaging facilitates accurate and controllable removal or sampling of the suspicious tissue so as to minimize trauma to surrounding healthy tissue. [0008]
  • For example, during a breast biopsy procedure, the biopsy device is often imaged with USI while the device is being inserted into the patient's breast and activated to remove a sample of suspicious breast tissue. As USI is often used to image tissue during follow-up treatment, it may be desirable to have a marker, similar to the radiographic markers discussed above, which can be placed in a patient's body at the site of a surgical procedure and which are visible using USI. However, radiopaque markers may not be visible with USI. A marker visible with USI enables a follow-up procedure to be performed without the need for traditional radiographic mammography imaging which, as discussed above, can be subject to inaccuracies as a result of shifting of the location wire as well as being tedious and uncomfortable for the patient. [0009]
  • Thus, there is need in the art for biopsy site markers that are deliverable into the cavity created by removal of the biopsy specimen and not into tissue that is located outside of that biopsy cavity, and which will not migrate from the biopsy cavity even when the breast tissue is moved, manipulated or decompressed. Moreover, such desired markers should remain detectable at the biopsy site (i.e., within the biopsy cavity for a desired time period); should not interfere with imaging of the biopsy site and adjacent tissues at a later time; and should be readily distinguishable in the various imaging procedures from lines of calcifications which frequently are signs for a developing malignancy. [0010]
  • SUMMARY OF INVENTION
  • The invention is directed to the deployment of a marker or filler forming material at intracorporeal locations such as biopsy sites, sites for cosmetic treatments and other sites which may need additional bulk. The marker or filler material is formed intracorporeally from a biocompatible solution having as a solute bioabsorbable polymeric material which is relatively insoluble in body fluid or other water based fluids and a water soluble, non-aqueous polar solvent such as dimethyl sulfoxide (DMSO). Suitable bioaborbable polymers include polylactic acid, polyglycolic acid, polycaprolactones and copolymers and blends thereof. When the marker or filler forming fluid contacts body fluid or other water based fluids present at intracorporeal locations, the non-aqueous solvent is quickly absorbed by the body fluid or water based fluid present at the site, precipitating a mass of the water insoluble bioabsorbable polymeric material at the site. The polymeric material forming the marker or filler mass is preferably inherently ultrasonically detectable or the marker fluid may be treated to have a plurality of gas bubbles or otherwise aerated, so that upon formation of the polymeric mass at the site, gas is incorporated in the solid mass forming to provide ultrasonically detectable porosity. [0011]
  • The following description of embodiments of the invention is primarily directed to deployment of mass at a biopsy site for purposes of remote detection of the biopsy site. However, it should be recognized that the invention may be employed to form filling or bulking masses at an intracorporeal locations for cosmetic and other uses, as previously alluded to. [0012]
  • After a biopsy specimen is removed from the patient, a guiding member such as a cannula or other tubular member is preferably left within the patient with the distal end thereof within or close to the biopsy site in order to provide subsequent access to the biopsy site. The tubular guiding member may be part of the biopsy system such as a SenoCor 360™ or a Mammotome® system which was used to separate the tissue specimen and remove it from the site but which remains in place after the specimen has been removed. The marker forming fluid embodying features of the invention, may be suitably delivered by a syringe with an elongated delivery tube which at least in part fits within a tubular guiding member leading to the biopsy site. [0013]
  • Generally, the amount of polymeric solute ranges from about 1 to about 50%, preferably about 10 to about 35% by weight of the marker or filler forming fluid. The ratio of the polymer solute to the solvent can be varied to adjust the delivery characteristics and the in-vivo lifetime (i.e. the time period in which the polymeric mass is at the biopsy site). For example a lower percentage of polymeric material in the mix will provide a softer or more friable marker mass within the cavity, whereas a higher percentage will provide a firmer marker mass. Lower percentages of solvent will provide thicker marker fluids which will not be readily displaced from the biopsy site, whereas higher percentages will provide a less viscous solution which is easier to deliver. High molecular weight polylactic acid provides a longer in-vivo life time, e.g. up to a year or more. A lower molecular weight polymeric material such as a copolymer of lactic acid (90%) and glycolic acid (10%) provides an in-vivo life time of about two to three weeks. A copolymer of lactic acid (65%) and glycolic acid (35%) with a molecular weight of about 60 kD has an in-vivo lifetime of about 12 to 14 weeks. [0014]
  • An ultrasound-detectable marker typically must remain in place and be remotely detectable within a patient for at least 2 weeks to have any practical clinical value. Thus, an ultrasound-detectable marker material embodying features of the invention is detectable at a biopsy site within a patient for a time period of at least 2 weeks, preferably at least about 6 weeks, and may remain detectable for a time period of up to about 20 weeks or more. An ultrasound-detectable marker mass embodying features of the invention is preferably not detectable after about one year, and usually not more than about 6 months after placement at a biopsy site. More preferably, the ultrasound-detectable marker mass should not be detectable with ultrasound after about 12 weeks from placement at a biopsy site. A preferable in-vivo lifetime for an ultrasound-detectable biopsy marker mass having features of the invention is about 6 weeks to about 12 weeks. [0015]
  • The detectable marker mass which forms in the biopsy cavity should be large enough to fill a substantial portion, preferably all of the cavity. This allows the detection and definition of the boundaries of the biopsy cavity. The accessing passageway leading to the biopsy cavity may also at least in part be filled with the marker fluid as well if desired, which allows the physician to follow to locate the marker mass. The marker mass which forms in the cavity is ultrasonically detectable, but the marker fluid may also include ultrasonically or radiographically detectable powders or other particulate to augment the detection of the polymeric mass or the biopsy cavity. Other therapeutic and diagnostic agents may be incorporated into the marker fluid such as pharmaceutical agents, chemotherapeutic agents, anesthetic agents, hemostatic agents, pigments, dyes, radiopaque agents, materials detectable by magnetic resonance imaging (MRI), inert materials, and other compounds. [0016]
  • In one embodiment of the invention, the delivery system is employed to incorporate a radiopaque or other type of long term or permanent marker element within the polymeric mass which forms in the biopsy cavity. For example, the distal end of the syringe assembly or the tubular guide member leading to the biopsy site may be provided with a distal tip which is formed of radiopaque or other suitable material and which is releasably secured to the distal portion of the syringe or guide member so that upon formation of the marker mass from the marker fluid, the distal tip of the syringe or guide member can be released within the formed polymer marker mass and the syringe or guide member then removed from the mass. [0017]
  • The biopsy site markers formed by the present invention provide ultrasonically bright images which can be readily distinguished from the ultrasound signals arising naturally from within a breast or other tissue and which readily contrasts with the dark ultrasound shadow region immediately behind the bright ultrasound echo region. The strength of the reflected signal, and the contrast with the shadow region, make the marked site readily detectable even to relatively inexperienced surgeons. The in-vivo lifetime of the marker at the biopsy site can be preselected by adjusting the amount of polymeric material in the marker fluid and the molecular weight thereof. The employment of the filler forming functions of the solution may be advantageously utilized in cosmetic treatments similar to the uses of collagen, e.g. wrinkle removal or minimization, or in situations in which additional bulk is needed within a patient's body, e.g., treating for urinary incontinence. [0018]
  • These and other advantages will be evident from the following detailed description when taken in conjunction with the accompanying exemplary drawings.[0019]
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is an elevational view, partially in section, of a marker fluid delivery system embodying features of the invention. [0020]
  • FIG. 1B is a transverse cross-sectional view taken along [0021] line 1B-1B shown in FIG. 1A.
  • FIG. 1C is a transverse cross-sectional view taken along [0022] line 1C-1C shown in FIG. 1A.
  • FIG. 1D is a transverse cross-sectional view taken along [0023] line 1D-1D shown in FIG. 1A.
  • FIG. 2 is a partially cut-away, perspective view of a system as illustrated in FIG. 1 shown depositing a marker fluid embodying features of the invention at a biopsy site within a breast of a female patient. [0024]
  • FIG. 3 is a perspective view, partially in section, of the distal portion of a delivery system having a releasable marker element on the distal tip of the delivery tube which acts as a long term or permanent marker. [0025]
  • FIG. 4 is a longitudinal, centerline cross-section of a delivery system having a releasable radiopaque distal tip. [0026]
  • FIG. 5 is a longitudinal, centerline cross-section of a delivery system having a releasable radiopaque distal tip which is threadably connected to the distal end of the delivery cannula and which has a grooved exterior to facilitate release of the distal tip. [0027]
  • FIG. 6 is a transverse cross-sectional view of the releasable distal tip shown in FIG. 5 taken along the lines [0028] 6-6.
  • FIG. 7 is an elevational view of a delivery cannula suitable for use to deliver the marker or filler forming fluid embodying features of the invention.[0029]
  • DETAILED DESCRIPTION OF THE INVENTION
  • FIGS. 1A-1D illustrate a [0030] system 10 for delivery of biopsy marker fluid 11 embodying features of the invention to a biopsy site within a patient's body. The system 10 includes a syringe 12 having a bore 13 containing a quantity of biopsy marker fluid 11. A plunger 14 with a sealable distal end 15 is slidably disposed within the bore 13 of syringe 12. Application of pressure to the head 16 of plunger 14 applies pressure to the fluid 11 and causes the discharge of fluid 11 from the bore 13 into the inner lumen 17 of delivery tube 18 secured to the discharge end of syringe 12. The marker fluid 11 passes through the inner lumen or bore 17 of the delivery tube 18 and out the discharge port 19 in the distal end of delivery tube 18.
  • As schematically illustrated in FIG. 1A, [0031] delivery tube 18 is secured to the syringe 12 by a friction fit. However, those skilled in the art will recognize that a variety of connections may be made between the syringe 12 and the delivery tube 18 such as a conventional luer-lock. The delivery tube 18 may have markings, such as lines or dots spaced at regular intervals along the length of the tube to indicate its position within the patient.
  • FIG. 2 illustrates the marker [0032] fluid delivery system 10 shown in FIGS. 1A-1D with the distal portion of the delivery tube 18 operatively disposed within a patient's breast 20 with the distal tip 21 of the delivery tube 18 disposed within biopsy cavity 22 at the biopsy site 23 ready to deliver marker fluid 11. An incision 24 in the breast 20 allows access to the cavity 22. Biopsy tubular guide member 25 extends through incision 24 in the patient's breast 20 into cavity 22 at biopsy site 23. The distal end 26 of syringe 12, containing marker fluid 11, is tightly engaged with delivery tube 18, which extends within guide member 25 so as to locate delivery tube outlet port 19 within biopsy cavity 22. The outer diameter of the delivery tube 18 is configured to allow the delivery tube to slidably fit inside the inner lumen 27 of biopsy guide member 25. Markings 28 spaced at regular intervals along the outer surface of delivery tube 18 indicate the depth of insertion of the tube within the guide member 25 and aid in the proper placement of discharge port 19 into position within cavity 22. Depression of plunger 14 of the syringe 12 forces marker fluid 11 out of syringe 12 through the inner lumen 17 of the delivery tube 18 and out port 19 into the cavity 22.
  • [0033] Fluid 11 mixes with body fluid or other water based fluid which may be present in the cavity 22. The solvent in fluid 11 is quickly dissolved in the body fluid or other water based fluid. The polymer solute which precipitates is relatively insoluble in the body fluid or other water based fluid which may be present in the cavity and forms a porous, ultrasonically detectable and bioabsorbable polymer mass 30 within the cavity 22. The mass 30 preferably essentially fills the biopsy cavity 22 so as to define the periphery of the biopsy cavity and to ensure that the mass remains within the biopsy cavity and will not migrate. The mass is subsequently absorbed by tissue and fluids near the biopsy site, so that at the end of the in-vivo life time of the bioabsorbable mass 30, the marker mass is no longer readily detectable at the site by ultrasonic means. Tissue ingrowth usually replaces the absorbed mass.
  • The preferred solvent for the fluid [0034] 11 is a pharmaceutical grade (USP) of DSMO. Other biocompatible water soluble, polar solvents are suitable. The preferred relatively water-insoluble bioabsorbable polymers are polylactic acid, poly glycolic acid, copolymers of lactic acid and glycolic acid, polycaprolactone. However, other suitable bioabsorbable, essentially water insoluble polymers include poly(esters), poly(hydroxy acids), poly(lactones), poly(amides), poly(ester-amides), poly(amino acids), poly(anhydrides), poly(ortho-esters), poly(carbonates), poly(phosphazines), poly(thioesters), poly(urethanes), poly(ester urethanes), polysaccharides, polylactic acid, polyglycolic acid, polycaproic acid, polybutyric acid, polyvaleric acid, and copolymers, polymer alloys, polymer mixtures, and combinations thereof.
  • The marker mass preferably essentially fills the biopsy cavity so as to define the periphery of the biopsy site cavity and to ensure that the marker mass remains within the biopsy cavity and will not migrate. The marker materials are resorbed by tissue and fluids near the biopsy site, so that, after their in-vivo life times, the marker materials are no longer USI-detectable at the biopsy site. [0035]
  • The marker fluid may also include radiopaque materials or radiopaque markers, so that the biopsy site may be detected both with ultrasound and with X-ray or other radiographic imaging techniques. Radiopaque materials and markers may include metal objects such as clips, bands, strips, coils, and other objects made from radiopaque metals and metal alloys, and may also include powders or particulate masses of radiopaque materials. Radiopaque markers may include liquid contrast agents such as Ethiodol or other non-water based contrast agents. Radiopaque markers may be of any suitable shape or size, and are typically formed in a recognizable shape not naturally found within a patient's body. Suitable radiopaque materials include stainless steel, platinum, gold, iridium, tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys and oxides of these metals, barium salts, iodine salts, iodinated materials, and combinations of these. The marker fluid may also include MRI-detectable materials or markers, so that the biopsy site may be detected with MRI techniques. MRI contrast agents such as gadolinium and gadolinium compounds, for example, are suitable for use with ultrasound-detectable biopsy marker materials embodying features of the invention. Colorants, such as dyes (e.g., methylene blue and carbon black) and pigments (e.g., barium sulfate), may also be included in the marker fluid of the invention. The colorant such as carbon black usually remains in the track or passageway leading to the marker or filler mass and this can be followed by the surgeon to the desired location. [0036]
  • Therapeutic agents to reduce bleeding, enhance clotting, to cause vasoconstriction, to prevent infections and other diseases, to reduce pain, chemotherapeutic agents to treat remnant cancer cells at the site may be incorporated into the marker fluid. Suitable therapeutic agents are provided in co-pending application Ser. No. 10/1214,757, filed on Jul. 27, 2002, which is incorporated herein in its entirety by reference. [0037]
  • FIGS. 3 and 4 depict the distal portion of an [0038] alternative delivery tube 30 which is disposed within tubular guide 31 and which has a releasable radiopaque element 32 on the distal tip of the delivery tube. A cannula 33 is slidably disposed about the delivery tube 30. Relative longitudinal movement between the cannula 33 and delivery tube 30, as depicted by arrows 34 and 35, pushes the radiopaque element 32 off the end of the tube into the cavity 36 as shown in FIG. 4. When the marker fluid 37 containing a non-aqueous, water soluble solvent and a relatively water insoluble polymeric solute is injected into the biopsy cavity 36 and the polymer mass is formed, the radiopaque element 32 is released from the delivery tube 30 and left within the polymer mass. The radiopaque element 32 is released within the polymer mass at a point in the formation of the mass which ensures that the position of the radiopaque element 32 is maintained after the distal end of the delivery tube 30 is removed from the cavity 36. Preferably, the radiopaque element 32 is centrally located within the biopsy cavity 36.
  • FIGS. 5 and 6 illustrate an alternative embodiment in which a releasable [0039] radiopaque element 40 is the distal tip of delivery tube 41. As shown, the element 40 is threadably connected to the distal portion of the delivery tube 41 and has a grooved exterior 42 which helps to fix the tip in the polymeric mass. This allows the delivery tube 41 to be unscrewed from the tip element 40 and to be withdrawn from the patient, leaving the radiopaque tip 40 within the polymeric mass.
  • The releasable radiopaque element may have a variety of other shapes which are recognizable as not being naturally found within a patient's body to facilitate remote detection radiographically or ultrasonically. For example, the radiopaque may have an exterior transverse shape such as a star or a square. The radiographically detectable distal tip may be formed of a suitable radiopaque material such as stainless steel, platinum, gold, iridium, tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys and oxides of these metals. Radiopaque salts such as barium salts, iodine salts, iodinated materials, and combinations of these may be incorporated into polymeric or ceramic materials which form the releasable tip. [0040]
  • As shown in FIG. 7, the deployment system may have a [0041] delivery tube 50 with a needle-like distal tip 51 to facilitate advancement of the delivery tube through tissue to the target site. This embodiment is particularly suitable in those situations in which there is no guide tube or other cannula in place to provide access to the target site.
  • Markers embodying features of the present invention remain detectable at an intracorporeal site for a desired time period, and degrade or dissolve so as to not interfere with imaging of the biopsy site and adjacent tissues at a later time. Suitable marker materials typically do not migrate from the biopsy site before being dissolved or otherwise absorbed, and so provide reliable temporary marking of the location of a biopsy site and the margins thereof. The marker materials having features of the invention are readily distinguishable from natural body features including signs of a developing or an actual malignancy. The present invention also includes apparatus and method for delivering markers to a biopsy site. [0042]
  • The purpose of markers embodying features of the invention is to facilitate the location and performance of a surgical procedure that is performed while the marker is still detectable. The in-vivo lifetime of the marker mass remaining in the biopsy cavity is relatively short, e.g. less than one year, preferably less than about six months. Typically, the marker mass should have an in-vivo life time of about 6 to about 20 weeks, preferably 6 to 12 weeks. The disappearance of a marker after a longer period of time is required to avoid obscuring or interfering with follow-up imaging or further mammography. [0043]
  • Typically, the marker fluid embodying features of the present invention containing ultrasound-detectable solute of bioabsorbable polymeric material of the present invention is deposited at a biopsy site within a patient's body to form a biopsy marker mass at the site to allow for the subsequent location of the site by medical personnel. Thus, for example, a quantity of fluid formed of a non-aqueous water soluble solvent such as DSMO with a bioabsorbable polymeric material which is essentially insoluble in body fluids or other water based fluids is delivered into a cavity at a biopsy site. When the solution comes into contact with body fluid or other water based fluid at the biopsy site, the solvent is quickly dissolved in the body fluid and the relatively water insoluble polymeric solute forms a marker mass within the biopsy cavity. [0044]
  • The in-vivo lifetime of the polymeric material, i.e. the time period in which the polymeric mass is ultrasonically detectable, is related to the molecular weight of the polymer. For example, copolymers of lactic and glycolic acids having an initial molecular weight of about 45,000 Daltons (45 kD) before processing, are suitable for use in making an ultrasound-detectable marker material having an in-vivo lifetime of about 12 weeks. As is known to those of ordinary skill in the art, other materials, including other polymeric materials, may require a different starting molecular weight in order to obtain the same in-vivo lifetime. For example, polyglycolic acid typically degrades faster than other materials and as such requires a substantially higher initial molecular weight than polylactic acid or polycaprolactone to obtain a similar in-vivo lifetime. [0045]
  • Many properties of a material affects the intensity of its ultrasound reflection, including density, physical structure, molecular material, and shape. For example, sharp edges, or multiple reflecting surfaces on or within an object differing in density from its surroundings enhances its ability to be detected by ultrasound. Interfaces separating materials of different densities, such as between a solid and a gas, produce strong ultrasound signals. [0046]
  • The methods of the present invention provide materials having a porosity effective to produce strong ultrasound signals when located within the patient's biopsy cavity. The polymeric material may naturally form a porous mass or porosity can be formed by introducing a gas into the material during processing of a material, by release of gas from within the material, or by directing a gas into a material or by incorporating a blowing agent. [0047]
  • A typical human breast has a substantial number of features that are visualized with ultrasound. These features all have characteristic signals. Fibrous tissue or ligaments tend to show up as bright streaks, fat seems to appear as a dark gray area, the glandular tissue appears as a mottled medium gray mass. Cancerous lesions typically appear as a darker area with a rough outer edge which has reduced through transmission of the ultrasound energy. One advantage of the ultrasound-detectable biopsy marker materials of the present invention is that the materials provide an ultrasound signal which can be readily differentiated from anatomic structures within the breast, so that the identification and marking of a biopsy cavity does not require extensive training and experience. [0048]
  • The delivery syringe and the delivery tube attached to the syringe may be sized to accept any volume of marker or filler forming fluid desired to be injected into the desired intracorporeal site. The average Mammotome® biopsy removes about 0.5 to about 2, typically about 1 ml of tissue. The volume of marker fluid introduced into the biopsy cavity which remains after the removal of the tissue specimen is about the same as the tissue volume removed. Use of more marker fluid typically leads to some filling of the accessing passageway as well as of the cavity at the biopsy site. Smaller volumes of marker fluid may be used for smaller cavities at a biopsy site, such as are created with a single SenoCor 360™ biopsy or an automated Tru-Cute® biopsy. [0049]
  • The solution embodying features of the invention may also be employed as a filler or bulking agent. For example, the filler forming fluid may be used in a manner similar to collagen for cosmetic purposes to minimize wrinkles, to fill pockmarks and other surface pits. The solution may also be used to bulk up an area of tissue for a variety of reasons. For example, if a radiation source for treating a tumor or a tumor site after removal of the tumor is located too close to the patient's skin, e.g. less than about 5 mm, the skin may be damaged or ultimately scarred by the irradiation. By deploying the filler forming fluid embodying features of the invention between the irradiation source and the skin, the damage or scarring to the skin can be reduced or eliminated. Depending upon the source of the radiation, either a single bolus or multiple bolus may be employed to bulk up the region and to displace the skin sufficiently to avoid damage. [0050]
  • The filler forming fluid embodying features of the invention may also be employed to provide a bulking mass about a urethra in the treatment of urinary incontinence, for a bulking mass about an anal sphincter for fecal incontinence and a bulking mass about an esophageal sphincter for gastroesophageal reflux disease. Other uses will become apparent to those skilled in the art. [0051]
  • While particular forms of the invention have been illustrated and described, it will be apparent that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited to the specific embodiments illustrated and shall be defined by the scope of the appended claims as broadly as the prior art will permit. Moreover, those skilled in the art will recognize that features shown in one embodiment may be utilized in other embodiments. Terms such a “element”, “member”, “device”, “sections”, “portion”, “section”, “steps” and words of similar import when used herein shall not be construed as invoking the provisions of 35 U.S.C. §112(6) unless the following claims expressly use the terms “means” or “step” followed by a particular function without specific structure or action. [0052]

Claims (78)

1. A biopsy marker forming fluid for forming a remotely detectable marker within a biopsy site comprising a solution containing at least in part a relatively water insoluble bioabsorbable polymeric solvent dissolved in a polar, non-aqueous, water soluble biocompatible solvent.
2. The biopsy marker forming fluid of claim 1 wherein the bioabsorbable polymeric material is selected from the group consisting of polylactic acid, polyglycolic acid, polycaprolactone and copolymers, blends and mixtures thereof.
3. The biopsy marker forming fluid of claim 2 wherein the polymeric material is a copolymer of polylactic acid and polyglycolic acid and the weight ratio of polylactic acid to polyglycolic acid is about 90:10 to about 60:40.
4. The biopsy marker forming fluid of claim 2, wherein the copolymer comprises 65% (by wt.) polylactic acid and 35% (by wt.) polyglycolic acid.
5. The biopsy marker forming fluid of claim 1 containing about 1 to about 50% by weight water insoluble, bioabsorbable polymeric solute.
6. The biopsy marker forming fluid of claim 8 containing about 10 to about 90% by weight water insoluble, bioatsorbable polymeric solute.
7. The biopsy marker forming fluid of claim 1 wherein the polar solvent is dimethyl sulfoxide.
8. After a biopsy procedure wherein one or more tissue specimens are removed from a target site of a human patient, a further procedure comprising delivering to the target site, a marker forming fluid suitable for intracorporeal deployment comprising a solution of a polar, non-aqueous, water soluble solvent and a relatively water insoluble, bioabsorbable polymeric solute.
9. The procedure of claim 8 wherein the solvent contains dimethyl sulfoxide.
10. The procedure of claim 8 wherein the relatively water insoluble, bioabsorbable solute is a polymeric material selected from the group consisting of polylactic acid, polyglycolic acid, polycaprolactone and copolymers, blends and mixtures thereof.
11. A biocompatible marker forming solution suitable for deployment within a biopsy site comprising a polar, non-aqueous solvent which is relatively soluble in a water based fluid and a bioabsorbable polymeric solute which is relatively insoluble in the water based fluid.
12. The biocompatible marker forming solution of claim 11 wherein the solvent is dimethyl sulfoxide.
13. The biocompatible marker forming solution of claim 11 wherein the water insoluble, bioabsorbable polymeric solute is selected from the group consisting of polylactic acid, polyglycolic acid, pcolycaprolactone, copolymers and blends thereof.
14. The biocompatible marker forming solution of claim 11 containing about 1 to about 35% by weight water insoluble, bioabsorbable polymeric solute.
15. The biocompatible marker forming solution of claim 11 containing about 10 to about 90% by weight water insoluble, bioabsorbable polymeric solute.
16. The biocompatible marker forming solution of claim 11 wherein the bioabsorbable polymeric solute forms a polymeric marker mass in-situ which is ultrasonically detectable when in a solid phase.
17. The biocompatible marker forming solution of claim 16 including a marker element or material which enables remote detection.
18. The biocompatible marker forming solution of claim 15 wherein the bioabsorbable polymeric material is selected from the group consisting of a poly(ester), a poly(hydroxy acid), a poly(lactone), a poly(amide), a poly(ester-amide), a poly(amino acid), a poly(anhydride), a poly(ortho-ster), a poly(carbonates), a poly(phosphazine), a poly(thioester), a poly(iurethane), a poly(ester urethane), a polysaccharide, a polylactic acid, a polyglycolic acid, a polycaproic acid, a polybutyric acid, a polyvaleric acid, and copolymers and blends thereof.
19. The biocompatible marker forming solution of claim 15, wherein said bioabsorbable polymeric material is selected from the group consisting of polylactic acids, polyglycolic acids, polycaproic acids, and copolymers and blends thereof.
20. The biocompatible marker forming solution of claim 15 wherein the bioabsorbable polymeric material has an average molecular weight of less than about 60 kD.
21. The biocompatible marker forming solution of claim 15 wherein the marker mass formed in contact with a water based fluid has an in-vivo lifetime of at least about 2 weeks.
22. The biocompatible marker forming solution of claim 15 wherein the marker mass formed in contact with a water based fluid has an in-vivo lifetime not greater than about a year.
23. The biocompatlble marker forming solution of claim 15, wherein the marker mass formed in contact with a water based fluid has an in-vivo lifetime not greater than about six months.
24. The biocompatible marker forming solution of claim 15, wherein the marker mass which forms in contact with a water based fluid has an in-vivo lifetime between about 6 weeks and about 12 weeks.
25. The biocompatible marker forming solution of claim 15 wherein the marker mass which forms in contact with a water based fluid includes a radiopaque element.
26. The biocompatible marker forming solution of claim 15 wherein the radiopaque element is formed of a material selected from the group consisting of stainless steel, platium, gold, indium, tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys of radiopaque metals, mixtures of radiopaque metals, oxides of radiopaque metals, barium salts, iodine salts, iodinated materials, and combinations thereof.
27. A system for marking a biopsy site within a patient, comprising:
a. a syringe having an elongated body, an inner bore, a plunger slidably disposed within the inner bore, and a discharge opening in a distal end;
b. a delivery tube having a proximal end configured to be secured to the distal end of the syringe, a bore in fluid communication with the inner bore of the syringe; and
c. a quantity of marker forming fluid within the bore of the syringe which comprises a solvent which is relatively soluable in a body fluid or other water based fluid and a bioabsorb polymeric solute which is relatively insoluble in body fluid or other water based fluid.
28. The system of claim 27, wherein the quantity of marker forming fluid in the inner bore of the syringe is about 0.2 ml to about 1.2 ml.
29. The system of claim 27 wherein the distal end of the delivery tube has a remotely detectable distal tip.
30. The system of claim 29 wherein the releasable distal tip is at least in part radiopaque.
31. The system of claim 29 wherein the radiopaque part of the releasable distal tip is formed of one or more materials selected from the group consisting of stainless steel, platinum, gold, iridium, tantalum, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys of radiopaque metals, mixtures of radiopaque metals, oxides of radiopaque metals, barium salts, iodine salts, iodinated materials, and combinations thereof.
32. The system of claim 29, wherein the marker forming fluid contains a radiopaque element.
33. The system of claim 32, wherein the radiopaque element is formed in a recognizable shape not naturally found within the patient's body.
34. The system of claim 27, wherein the polymeric solute is at least in part a copolyermer of poly-lactic acid and poly-glycolic acid.
35. The system of claim 27, wherein the marker forming fluid includes at least one agent selected from the group of agents consisting of thereapeutic or diagnostic agents.
36. The system of claim 35 wherein the agents include hemostatic agents, radiopaque contrast agents, and coloring agents.
37. The system of claim 27 wherein the marker forming fluid includes a radioactive element.
38. The system of claim 37 wherein the radioactive element is a brachytherapy seed.
39. The biocompatable fluid for forming a marker or filler mass in a non-vascular, intracorporeal location within a patient's body, comprising a solution having a relatively water insoluable bioabsorbable polymeric solute and a polar water soluable solvent.
40. A method of forming a filter mass at an intracorporeal site within a patient, comprising delivering to the intracorporeal site a filler forming biocompatable solution of a polar, non-aqueous, water soluble solvent and a relatively water insoluble, bioabsorbable polymeric solute.
41. The method of claim 40 wherein the solvent is dimethyl sulfoxide.
42. The method of claim 40 wherein the relatively water insoluble, bioabsorbable solute is a polymeric material selected from the group consisting of polyactic acid, polyglycolic acid, polycaprolactone and copolymers, blends and mixtures thereof.
43. The method of claim 40 wherein the intracorporeal site is adjacent to the patient's urethra.
44. The method of claim 40 wherein the intracorporeal site is adjacent to the patient's esophageal sphincter.
45. The method of claim 40 wherein the intracorporeal site is adjacent to the patient's anal sphincter.
46. The method of claim 40 wherein the intracorporeal site is underneath the patient's facial skin.
47. A intracorporeal mass forming fluid comprising a solution containing at least in part a relatively water insoluable bioabsorbable polymeteric solvent dissolved in a polar, non-aqueous, water soluable biocompatable solvent.
48. The intracorporeal mass forming fluid of claim 47 wherein the bioabsorbable polymeric material is selected from the group consisting of polylactic acid, polyglycolic acid, polycaprolactone and copolymers, blends and mixtures thereof.
49. The intracorporeal mass forming fluid of claim 48 wherein the polymeric material is a copolymer of polylactic acid and polyglycolic acid and the weight ratio of polyactic acid to polyglycolic acid is about 90:10 to about 60:40.
50. The intracorporeal mass forming acid fluid of claim 48, wherein the copolymer comprises 65% (by wt.) polylactic acid and 35% (by wt.) polyglycolic acid.
51. The intracorporeal mass forming fluid of claim 47 containing about 1 to about 50% by weight water insoluble, bioabsorbable polymeric solute.
52. The intracorporeal mass forming fluid in claim 51 containing about 10 to about 90% by weight water insoluble, bioabsorbable polymeric solute.
53. The intercorporeal mass forming fluid of claim 47 wherein the polar solvent is dimethyl sulfoxide.
54. After a biopsy procedure wherein one or more tissue specimens are removed from a target site of a human patient, a further procedure comprising delivering to the target site, a mass forming fluid suitable for intracorporeal deployment comprising a solution of a polar, non-aqueous, water soluable solvent and a relatively water insoluable, bioabsorbable polymeric solute.
55. The procedure of claim 54 wherein the solvent contains dimethyl sulfoxide.
56. The procedure of claim 54 wherein the relatively water insoluable, bioabsorbable solute is a polymeric material selected from the group consisting of polylactic acid, polyglycolic acid, polycaprolactone and copolymers, blends and mixtures thereof.
57. A biocompatible mass forming solution suitable for deployment within a biopsy site comprising a polar, non-aqueous solvent which is relatively soluble in a water based fluid and a bioabsorbable polymeric solute which is relatively insoluble in the water based fluid.
58. The biocompatable mass forming solution of claim 57 wherein the solvent is dimethyl sulfoxide.
59. The biocompatible mass forming solution of claim 57 wherein the water insoluble bioabsorbable polymeric solute is selected from the group consisting of polylactic acid, polyglycolic acid, polycaprolactone, copolymers and blends thereof.
60. The biocompatable mass forming solution of claim 57 containing about 1 to about 35% by weight water insoluble, bioabsorbable polymeric solute.
61. The biocompatible mass forming solution of claim 57 containing about 10 to about 90% by weight water insoluble, bioabsorbable polymeric solute.
62. The biocompatible mass forming solution of claim 57 wherein the bioabsorbable polymeric solute forms a polymeric mass in-situ which is ultrasonically detectable when in a solid phase.
63. The biocompatible mass forming solution of claim 57 including a marker element or material which enables remote detection.
64. The biocompatible mass forming solution of claim 61 wherein the bioabsorbable polymeric material is selected from the group consisting of a poly(ester), a poly(hydroxy acid), a poly(lactone), a poly(amide), a poly(ester-amide), a poly(amino acid), a poly(anhydride), a poly(ortho-ester), a poly(carbonates), a poly(phosphazine), a poly(thioester), a poly(urethane), a poly(ester urethane), a polysaccharide, a polyactic acid, a polyglycolic acid, a polycaproic acid, a polybutric acid, a polyvaleric acid and copolymers and blends thereof.
65. The biocompatible mass forming solution of claim 61, wherein said bioabsorbable polymeric material is selected from the group consisting of polylactic acids, polyglycolic acids, polycaproic acids, and copolymers and blends thereof.
66. The biocompabible mass forming solution of claim 61 wherein the bioabsorbable polymeric material has an average molecular weight of less than about 60 kD.
67. The biocompatible mass forming solution of claim 61 wherein the mass formed in contact with a water based fluid has an in-vivo lifetime of at least about 2 weeks.
68. The biocompatible mass forming solution of claim 61 wherein the mass formed in contact with a water based fluid has an in-vivo lifetime not greater than about a year.
69. The biocompatible mass forming solution of claim 61, wherein the mass formed in contact with a water based fluid has an in-vivo lifetime not greater than about six months.
70. The biocompatible mass forming solution of claim 61, wherein the mass which forms in contact with a water based fluid has an in-vivo lifetime between about 6 weeks and about 12 weeks.
71. The biocompatible mass forming solution of claim 61 wherein the mass which forms in contact with a water based fluid includes a radiopaque element.
72. The biocompatible mass forming solution of claim 61 wherein the radiopaque element is formed of a material selected from the group consisting of stainless steel, platinum, gold, indium, tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaque metals, alloys of radiopaque metals, mixtures of radiopaque metals, oxides of radiopaque metals, barium salts, iodine salts, iodinated materials, and combinations thereof.
73. A method of irradiating a patient's tissue at a first intracorporeal site without damaging tissue proximal to the first intracorporeal site, comprising
providing an irradiation source at the first intracorporeal site; and
forming a bulking mass within the patient at a second intracorporeal site between
the first intracorporeal site and tissue proximate thereto by delivering to
the second introcorporeal site a filler forming biocompatible solution of a
polar, non-aqueous, water soluble solvent and a relatively water insoluble,
bioabsorbable polymeric solute.
74. The method of claim 73 wherein the solvent is dimethyl sulfoxide.
75. The method of claim 73 wherein the relatively water insoluble, bioabsorbable solute is a polymeric material selected from the group consisting of polylactic acid, polyglycolic acid, polyaproactone and copolymers, blends and mixtures thereof.
76. The method of claim 73 wherein the first intracorporeal site is adjacent to a tumor site or a site from which a tumor has been removed.
77. The method of claim 73 wherein the first intracorporeal site is not more than about 5 mm from the tissue proximate to the first introcorporeal site which might be damaged by the irradiation.
78. The method of claim 77 wherein the tissue proximal to the first intracorporeal site which might be damaged by the irradiation is skin tissue overlying the first intracorporeal site.
US10/444,428 2003-05-23 2003-05-23 Marker or filler forming fluid Active 2025-07-09 US7877133B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/444,428 US7877133B2 (en) 2003-05-23 2003-05-23 Marker or filler forming fluid
PCT/US2004/014731 WO2004105803A1 (en) 2003-05-23 2004-05-12 Marker or filler forming fluid for use in biopsy procedures
US12/214,947 US10299881B2 (en) 2003-05-23 2008-06-24 Marker or filler forming fluid
US12/967,639 US8447386B2 (en) 2003-05-23 2010-12-14 Marker or filler forming fluid
US13/895,927 US8639315B2 (en) 2003-05-23 2013-05-16 Marker or filler forming fluid
US14/143,738 US10045832B2 (en) 2003-05-23 2013-12-30 Marker or filler forming fluid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/444,428 US7877133B2 (en) 2003-05-23 2003-05-23 Marker or filler forming fluid

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/214,947 Division US10299881B2 (en) 2003-05-23 2008-06-24 Marker or filler forming fluid
US12/967,639 Continuation US8447386B2 (en) 2003-05-23 2010-12-14 Marker or filler forming fluid

Publications (2)

Publication Number Publication Date
US20040236211A1 true US20040236211A1 (en) 2004-11-25
US7877133B2 US7877133B2 (en) 2011-01-25

Family

ID=33450656

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/444,428 Active 2025-07-09 US7877133B2 (en) 2003-05-23 2003-05-23 Marker or filler forming fluid
US12/214,947 Active 2025-04-04 US10299881B2 (en) 2003-05-23 2008-06-24 Marker or filler forming fluid
US12/967,639 Expired - Lifetime US8447386B2 (en) 2003-05-23 2010-12-14 Marker or filler forming fluid
US13/895,927 Expired - Lifetime US8639315B2 (en) 2003-05-23 2013-05-16 Marker or filler forming fluid
US14/143,738 Active 2024-10-09 US10045832B2 (en) 2003-05-23 2013-12-30 Marker or filler forming fluid

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/214,947 Active 2025-04-04 US10299881B2 (en) 2003-05-23 2008-06-24 Marker or filler forming fluid
US12/967,639 Expired - Lifetime US8447386B2 (en) 2003-05-23 2010-12-14 Marker or filler forming fluid
US13/895,927 Expired - Lifetime US8639315B2 (en) 2003-05-23 2013-05-16 Marker or filler forming fluid
US14/143,738 Active 2024-10-09 US10045832B2 (en) 2003-05-23 2013-12-30 Marker or filler forming fluid

Country Status (2)

Country Link
US (5) US7877133B2 (en)
WO (1) WO2004105803A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030233101A1 (en) * 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US20040024333A1 (en) * 2002-07-26 2004-02-05 Stuart Brown Tissue and fluid sampling device
US20040236213A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Marker delivery device with releasable plug
US20040249278A1 (en) * 2003-06-04 2004-12-09 Krause William R. Biopsy and delivery device
US20060036165A1 (en) * 1999-02-02 2006-02-16 Senorx, Inc. Tissue site markers for in vivo imaging
US20060084865A1 (en) * 1999-02-02 2006-04-20 Burbank Fred H Imageable biopsy site marker
US20070110665A1 (en) * 2005-11-17 2007-05-17 Bolan Patrick J Tissue marker for multimodality radiographic imaging
US20070118034A1 (en) * 2005-11-22 2007-05-24 Mark Joseph L Surgical site marker delivery system
US20070123815A1 (en) * 2005-09-28 2007-05-31 Mark Joseph L System and method for minimally invasive disease therapy
US20080281388A1 (en) * 1997-10-10 2008-11-13 John Corbitt Method of utilizing an implant for targeting external beam radiation
US20090149746A1 (en) * 2007-11-19 2009-06-11 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US20090217932A1 (en) * 2008-03-03 2009-09-03 Ethicon Endo-Surgery, Inc. Intraluminal tissue markers
US20100082102A1 (en) * 2008-09-23 2010-04-01 Senorx, Inc. Porous bioabsorbable implant
US7792569B2 (en) 1999-02-02 2010-09-07 Senorx, Inc. Cavity-filling biopsy site markers
WO2011009077A2 (en) * 2009-07-16 2011-01-20 Trustees Of Boston University Labeled skin lesion biopsy punch and uses thereof
US20110077512A1 (en) * 2009-06-16 2011-03-31 Dept. Of Veterans Affairs Biopsy marker composition and method of use
WO2011163591A1 (en) * 2010-06-25 2011-12-29 Kci Licensing, Inc. Systems and methods for imaging sinuses
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US8718745B2 (en) 2000-11-20 2014-05-06 Senorx, Inc. Tissue site markers for in vivo imaging
US20140171385A1 (en) * 2012-12-14 2014-06-19 Ecd Medical Materials for Short-Term Use in Mammals
US9149341B2 (en) 1999-02-02 2015-10-06 Senorx, Inc Deployment of polysaccharide markers for treating a site within a patient
US9795455B2 (en) 2014-08-22 2017-10-24 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
CN110267600A (en) * 2017-02-06 2019-09-20 设备与设计有限责任公司 System, the method and apparatus placed for integrated organization sampling and tissue markers
US20190321014A1 (en) * 2005-08-10 2019-10-24 C. R. Bard, Inc. Single-insertion, multiple sampling biopsy device usable with various transport systems and integrated markers
EP3723618A4 (en) * 2017-12-11 2021-12-15 Hologic, Inc. Ultrasound localization system with advanced biopsy site markers
US11241296B2 (en) 2005-11-17 2022-02-08 Breast-Med, Inc. Imaging fiducial markers and methods
US11359103B2 (en) 2008-11-07 2022-06-14 Viscot Medical, Llc Scrub-resistant ink and methods and apparatus for fabrication and use thereof

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
US8064987B2 (en) 2006-10-23 2011-11-22 C. R. Bard, Inc. Breast marker
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
WO2009099767A2 (en) 2008-01-31 2009-08-13 C.R. Bard, Inc. Biopsy tissue marker
BRPI0823399B8 (en) 2008-12-30 2021-06-22 Bard Inc C R marker release device for tissue marker positioning
US10634741B2 (en) 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
US9427186B2 (en) 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US8554309B2 (en) * 2010-09-23 2013-10-08 Hologic, Inc. Localizing obturator with site marking capability
US10004483B2 (en) 2012-10-11 2018-06-26 Pave, Llc Scoop cannula for a coring biopsy device
JP6351639B2 (en) 2013-03-11 2018-07-04 エンドマグネティクス リミテッド Hypotonic solution for lymph node detection
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
WO2016196597A1 (en) * 2015-06-04 2016-12-08 The University Of Florida Research Foundation, Inc. Coaxial biopsy needles
CN113558782A (en) 2015-06-04 2021-10-29 安都磁学有限公司 Marker materials and forms for Magnetic Marker Localization (MML)
US10610841B1 (en) 2016-06-30 2020-04-07 Devicor Medical Products, Inc. Marker having enhanced ultrasound visibility and method of manufacturing the same
US20180289467A1 (en) * 2017-04-05 2018-10-11 Ernesto Andrade Dispensing device, kit, and method for tissue augmentation
WO2019067441A1 (en) 2017-09-26 2019-04-04 Devicor Medical Products, Inc. Biopsy site marker with microsphere coating
USD868968S1 (en) * 2018-07-04 2019-12-03 Steve A. Haworth Mammary papilla implant
JP7279149B2 (en) 2019-05-08 2023-05-22 アトリキュア, インコーポレイテッド Locating and marking biological tissue locations
EP4143738A4 (en) * 2020-05-01 2024-03-13 Endoglow Prime Llc Near infrared breast tumor marker
CN112043409B (en) * 2020-09-30 2021-07-06 河南省中医院(河南中医药大学第二附属医院) Tumor marking injector

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2192270A (en) * 1938-05-25 1940-03-05 American Brake Co Brake rigging
US3341417A (en) * 1965-07-14 1967-09-12 Edwin S Sinaiko Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators
US3818894A (en) * 1971-01-22 1974-06-25 Ceskoslovenska Akademie Ved Laryngeal implant
US3823212A (en) * 1968-11-27 1974-07-09 Freudenberg C Fa Process for the production of collagen fiber fabrics in the form of felt-like membranes or sponge-like layers
US4007732A (en) * 1975-09-02 1977-02-15 Robert Carl Kvavle Method for location and removal of soft tissue in human biopsy operations
US4172449A (en) * 1978-05-01 1979-10-30 New Research And Development Laboratories, Inc. Body fluid pressure monitor
US4197846A (en) * 1974-10-09 1980-04-15 Louis Bucalo Method for structure for situating in a living body agents for treating the body
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4294241A (en) * 1977-06-09 1981-10-13 Teruo Miyata Collagen skin dressing
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4545367A (en) * 1982-07-16 1985-10-08 Cordis Corporation Detachable balloon catheter and method of use
US4647480A (en) * 1983-07-25 1987-03-03 Amchem Products, Inc. Use of additive in aqueous cure of autodeposited coatings
US4693237A (en) * 1986-01-21 1987-09-15 Hoffman Richard B Radiopaque coded ring markers for use in identifying surgical grafts
US4813062A (en) * 1986-08-13 1989-03-14 Milliken Research Corporation Radio-opaque marker and method
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
US4863470A (en) * 1985-03-19 1989-09-05 Medical Engineering Corporation Identification marker for a breast prosthesis
US4889707A (en) * 1988-01-29 1989-12-26 The Curators Of The University Of Missouri Composition and method for radiation synovectomy of arthritic joints
US4909250A (en) * 1988-11-14 1990-03-20 Smith Joseph R Implant system for animal identification
US4938763A (en) * 1988-10-03 1990-07-03 Dunn Richard L Biodegradable in-situ forming implants and methods of producing the same
US5137928A (en) * 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5147307A (en) * 1991-06-17 1992-09-15 Gluck Seymour M Anatomical marker device and method
US5221269A (en) * 1990-10-15 1993-06-22 Cook Incorporated Guide for localizing a nonpalpable breast lesion
US5236410A (en) * 1990-08-02 1993-08-17 Ferrotherm International, Inc. Tumor treatment method
US5281408A (en) * 1991-04-05 1994-01-25 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5282781A (en) * 1990-10-25 1994-02-01 Omnitron International Inc. Source wire for localized radiation treatment of tumors
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5368030A (en) * 1992-09-09 1994-11-29 Izi Corporation Non-invasive multi-modality radiographic surface markers
US5395319A (en) * 1991-03-06 1995-03-07 Suddeutsche Feinmechanik Gmbh Needle for inserting an object into the body
US5394875A (en) * 1993-10-21 1995-03-07 Lewis; Judith T. Automatic ultrasonic localization of targets implanted in a portion of the anatomy
US5422730A (en) * 1994-03-25 1995-06-06 Barlow; Clyde H. Automated optical detection of tissue perfusion by microspheres
US5433204A (en) * 1993-11-16 1995-07-18 Camilla Olson Method of assessing placentation
US5451406A (en) * 1994-07-14 1995-09-19 Advanced Uroscience, Inc. Tissue injectable composition and method of use
US5469847A (en) * 1992-09-09 1995-11-28 Izi Corporation Radiographic multi-modality skin markers
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
US5538726A (en) * 1992-02-28 1996-07-23 Order; Stanley E. Method and compositions for delivering cytotoxic agents to cancer
US5549560A (en) * 1992-05-13 1996-08-27 Wijdeven Gijsbertus G P Van De Apparatus and method for injecting a pharmaceutical preparation in solid form
US5580568A (en) * 1995-07-27 1996-12-03 Micro Therapeutics, Inc. Cellulose diacetate compositions for use in embolizing blood vessels
US5636255A (en) * 1996-03-05 1997-06-03 Queen's University At Kingston Method and apparatus for CT image registration
US5643246A (en) * 1995-02-24 1997-07-01 Gel Sciences, Inc. Electromagnetically triggered, responsive gel based drug delivery device
US5646146A (en) * 1993-02-02 1997-07-08 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5667767A (en) * 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5676146A (en) * 1996-09-13 1997-10-14 Osteotech, Inc. Surgical implant containing a resorbable radiopaque marker and method of locating such within a body
US5676925A (en) * 1992-03-06 1997-10-14 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5688490A (en) * 1991-02-15 1997-11-18 Bracco International B.V. Mucoadhesive compositions for increasing the ultrasonic image contrast of the digestive tract
US5695480A (en) * 1996-07-29 1997-12-09 Micro Therapeutics, Inc. Embolizing compositions
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
US5762903A (en) * 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
US5782775A (en) * 1995-10-20 1998-07-21 United States Surgical Corporation Apparatus and method for localizing and removing tissue
US5823198A (en) * 1996-07-31 1998-10-20 Micro Therapeutics, Inc. Method and apparatus for intravasculer embolization
US5853366A (en) * 1996-07-08 1998-12-29 Kelsey, Inc. Marker element for interstitial treatment and localizing device and method using same
US5902310A (en) * 1996-08-12 1999-05-11 Ethicon Endo-Surgery, Inc. Apparatus and method for marking tissue
US5942209A (en) * 1996-03-11 1999-08-24 Focal, Inc. Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US6231615B1 (en) * 1997-10-14 2001-05-15 Parallax Medical, Inc. Enhanced visibility materials for implantation in hard tissue
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6270464B1 (en) * 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
US6316522B1 (en) * 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6336904B1 (en) * 1998-04-07 2002-01-08 Pro Duct Health, Inc. Methods and devices for the localization of lesions in solid tissue
US6347241B2 (en) * 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US6350244B1 (en) * 2000-02-21 2002-02-26 Biopsy Sciences, Llc Bioabsorable markers for use in biopsy procedures
US6356782B1 (en) * 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6371904B1 (en) * 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6394965B1 (en) * 2000-08-15 2002-05-28 Carbon Medical Technologies, Inc. Tissue marking using biocompatible microparticles
US20020095205A1 (en) * 2001-01-12 2002-07-18 Edwin Tarun J. Encapsulated radiopaque markers
US6450937B1 (en) * 1999-12-17 2002-09-17 C. R. Bard, Inc. Needle for implanting brachytherapy seeds
US20020188196A1 (en) * 1999-02-02 2002-12-12 Burbank Fred H. Cavity-filling biopsy site markers
US6537193B1 (en) * 1998-06-17 2003-03-25 Scimed Life Systems, Inc. Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6605047B2 (en) * 2001-09-10 2003-08-12 Vivant Medical, Inc. Biopsy marker delivery system
US20030165478A1 (en) * 2002-02-14 2003-09-04 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US20030233101A1 (en) * 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US20040002650A1 (en) * 2001-06-20 2004-01-01 Evgenia Mandrusov Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US6766186B1 (en) * 1999-06-16 2004-07-20 C. R. Bard, Inc. Post biospy tissue marker and method of use
US20040213756A1 (en) * 2003-04-15 2004-10-28 Michal Eugene T. Methods and compositions to treat myocardial conditions
US20050065453A1 (en) * 2003-02-24 2005-03-24 Senorx, Inc. Biopsy device with selectable tissue receiving aperture orientation and site illumination

Family Cites Families (452)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2899362A (en) 1959-08-11 Hemostatic sponges and method of
US2481408A (en) * 1946-08-13 1949-09-06 Olin Mathieson Regeneration of caustic soda-sodium sulfide cooking liquor
GB708148A (en) 1950-12-18 1954-04-28 Hoechst Ag Hemostatic preparations and process for the manufacture thereof
DE1029528B (en) 1954-01-30 1958-05-08 Med H C Ernst Pohl Dr Device for marking a drill hole to be made, especially for bone nails and bone screws
US2832888A (en) * 1956-05-17 1958-04-29 David R Houston Box car detector
US2907327A (en) 1957-02-08 1959-10-06 Pfizer & Co C Pellet implanter
US3005457A (en) 1957-04-01 1961-10-24 Ortho Pharma Corp Methyl cellulose sponge and method of making
US3128744A (en) 1963-01-02 1964-04-14 Keith B Jefferts Method for investigating the migratory habits of macro-organisms
US3516412A (en) 1965-08-16 1970-06-23 Electro Catheter Corp Bipolar electrode having irregularity at inserting end thereof and method of insertion
US3402712A (en) 1966-07-19 1968-09-24 American Home Prod Pellet implanter
US3593343A (en) * 1968-07-19 1971-07-20 Robert F Viggers Prosthetic ball-check heart valve
US3757781A (en) * 1971-09-17 1973-09-11 R Smart Tool for administering pills to animals
US3820545A (en) 1973-03-26 1974-06-28 K Jefferts Tag implanting machine
US3892731A (en) 1973-11-23 1975-07-01 Univ Delaware Solvents for and purification of chitin
US3921632A (en) 1974-08-16 1975-11-25 Frank M Bardani Implant device
US4005699A (en) 1974-10-09 1977-02-01 Louis Bucalo Methods and apparatus for use in magnetic treatment of the body
US4041931A (en) 1976-05-17 1977-08-16 Elliott Donald P Radiopaque anastomosis marker
US4217889A (en) 1976-09-15 1980-08-19 Heyer-Schulte Corporation Flap development device and method of progressively increasing skin area
US4105030A (en) 1977-01-03 1978-08-08 Syntex (U.S.A.) Inc. Implant apparatus
US4086914A (en) 1977-02-11 1978-05-02 Edwin Bailey Moore Implant injector
US4103690A (en) 1977-03-21 1978-08-01 Cordis Corporation Self-suturing cardiac pacer lead
US4127774A (en) 1977-06-20 1978-11-28 Jerry Gillen X-ray marker
SU745505A1 (en) 1977-09-28 1980-07-05 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Method of guiding stereotaxic tool on target point
DE2843963A1 (en) 1978-10-09 1980-04-24 Merck Patent Gmbh BODY-RESORBABLE SHAPED MATERIAL BASED ON COLLAGEN AND THEIR USE IN MEDICINE
US4588395A (en) 1978-03-10 1986-05-13 Lemelson Jerome H Catheter and method
US4390018A (en) 1980-09-15 1983-06-28 Zukowski Henry J Method for preventing loss of spinal fluid after spinal tap
US4442843A (en) 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
US4470160A (en) 1980-11-21 1984-09-11 Cavon Joseph F Cast gel implantable prosthesis
US4740208A (en) 1980-11-21 1988-04-26 Cavon Joseph F Cast gel implantable prosthesis
US4428082A (en) 1980-12-08 1984-01-31 Naficy Sadeque S Breast prosthesis with filling valve
US4298998A (en) 1980-12-08 1981-11-10 Naficy Sadeque S Breast prosthesis with biologically absorbable outer container
US4487209A (en) 1981-03-16 1984-12-11 Creative Research And Manufacturing Inc. Biopsy needle
US4401124A (en) 1981-08-13 1983-08-30 Technicare Corporation Reflection enhancement of a biopsy needle
US4400170A (en) 1981-09-29 1983-08-23 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4582061A (en) 1981-11-18 1986-04-15 Indianapolis Center For Advanced Research, Inc. Needle with ultrasonically reflective displacement scale
US4582640A (en) 1982-03-08 1986-04-15 Collagen Corporation Injectable cross-linked collagen implant material
US4405314A (en) 1982-04-19 1983-09-20 Cook Incorporated Apparatus and method for catheterization permitting use of a smaller gage needle
US5542915A (en) 1992-08-12 1996-08-06 Vidamed, Inc. Thermal mapping catheter with ultrasound probe
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
GB2138298B (en) 1983-04-21 1986-11-05 Hundon Forge Ltd Pellet implanter
US4655226A (en) 1983-12-16 1987-04-07 Southland Instruments, Inc. Disposable biopsy needle unit
CH661199A5 (en) 1983-12-22 1987-07-15 Sulzer Ag MARKING IMPLANT.
US4549560A (en) * 1984-03-19 1985-10-29 Andis Company Hair curling appliance with elastomer material covering heating element
CA1295796C (en) 1984-03-27 1992-02-18 Conrad Whyne Biodegradable matrix and methods for producing same
US4648880A (en) 1984-08-30 1987-03-10 Daniel Brauman Implantable prosthetic devices
US4963150B1 (en) 1984-08-30 1994-10-04 Daniel Brauman Implantable prosthetic device
US4820267A (en) 1985-02-19 1989-04-11 Endocon, Inc. Cartridge injector for pellet medicaments
US5628781A (en) 1985-06-06 1997-05-13 Thomas Jefferson University Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves
US4682606A (en) 1986-02-03 1987-07-28 Decaprio Vincent H Localizing biopsy apparatus
US4661103A (en) 1986-03-03 1987-04-28 Engineering Development Associates, Ltd. Multiple implant injector
US4832680A (en) 1986-07-03 1989-05-23 C.R. Bard, Inc. Apparatus for hypodermically implanting a genitourinary prosthesis
DE3789320T2 (en) 1986-07-30 1994-06-09 Sumitomo Pharma Administration instrument for the introduction of solid medication.
US4931059A (en) 1986-11-24 1990-06-05 Markham Charles W Needle/stylet combination
US4762128A (en) 1986-12-09 1988-08-09 Advanced Surgical Intervention, Inc. Method and apparatus for treating hypertrophy of the prostate gland
US4994028A (en) 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
US4874376A (en) 1987-04-13 1989-10-17 Hawkins Jr Irvin F Needle guide assembly
US4950234A (en) 1987-05-26 1990-08-21 Sumitomo Pharmaceuticals Company, Limited Device for administering solid preparations
US4989608A (en) 1987-07-02 1991-02-05 Ratner Adam V Device construction and method facilitating magnetic resonance imaging of foreign objects in a body
US5035891A (en) 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
US5120802A (en) 1987-12-17 1992-06-09 Allied-Signal Inc. Polycarbonate-based block copolymers and devices
US4870966A (en) 1988-02-01 1989-10-03 American Cyanamid Company Bioabsorbable surgical device for treating nerve defects
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
EP0398935B1 (en) 1988-02-05 1994-08-10 Schering Aktiengesellschaft Ultrasonic contrast agents, process for producing them and their use as diagnostic and therapeutic agents
US5374261A (en) 1990-07-24 1994-12-20 Yoon; Inbae Multifunctional devices for use in endoscopic surgical procedures and methods-therefor
US4994013A (en) 1988-07-28 1991-02-19 Best Industries, Inc. Pellet for a radioactive seed
US5444113A (en) 1988-08-08 1995-08-22 Ecopol, Llc End use applications of biodegradable polymers
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JPH0545458Y2 (en) 1988-10-25 1993-11-19
US4950665A (en) 1988-10-28 1990-08-21 Oklahoma Medical Research Foundation Phototherapy using methylene blue
JPH02131757A (en) 1988-11-11 1990-05-21 Olympus Optical Co Ltd Cutting implement for surgery
US5800541A (en) 1988-11-21 1998-09-01 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5475052A (en) 1988-11-21 1995-12-12 Collagen Corporation Collagen-synthetic polymer matrices prepared using a multiple step reaction
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
AU5154390A (en) 1989-02-15 1990-09-05 Microtek Medical, Inc. Biocompatible material and prosthesis
US5141748A (en) 1989-02-17 1992-08-25 Hoffmann-La Roche, Inc. Implant drug delivery device
US5081997A (en) 1989-03-09 1992-01-21 Vance Products Incorporated Echogenic devices, material and method
US5201314A (en) 1989-03-09 1993-04-13 Vance Products Incorporated Echogenic devices, material and method
US5289831A (en) 1989-03-09 1994-03-01 Vance Products Incorporated Surface-treated stent, catheter, cannula, and the like
US5025797A (en) 1989-03-29 1991-06-25 Baran Gregory W Automated biopsy instrument
GB2230191B (en) 1989-04-15 1992-04-22 Robert Graham Urie Lesion location device
DE8905585U1 (en) 1989-05-03 1989-06-29 Bosch-Siemens Hausgeraete Gmbh, 8000 Muenchen, De
US5012818A (en) 1989-05-04 1991-05-07 Joishy Suresh K Two in one bone marrow surgical needle
US5018530A (en) 1989-06-15 1991-05-28 Research Corporation Technologies, Inc. Helical-tipped lesion localization needle device and method of using the same
US5197482A (en) 1989-06-15 1993-03-30 Research Corporation Technologies, Inc. Helical-tipped lesion localization needle device and method of using the same
US5234426A (en) 1989-06-15 1993-08-10 Research Corporation Technologies, Inc. Helical-tipped lesion localization needle device and method of using the same
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5284479A (en) 1989-08-30 1994-02-08 N.V. Nederlandsche Apparatenfabriek Nedap Implanter
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5201704A (en) 1989-11-07 1993-04-13 Ray Joel W Method of making and using a hemostatic agent applicator
JPH03158171A (en) 1989-11-17 1991-07-08 Masataka Saito Cap integral type disposal injection needle
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5197846A (en) * 1989-12-22 1993-03-30 Hitachi, Ltd. Six-degree-of-freedom articulated robot mechanism and assembling and working apparatus using same
GB9003821D0 (en) 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
JPH042372U (en) * 1990-04-23 1992-01-09
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
EP0475077B1 (en) 1990-09-10 1996-06-12 Synthes AG, Chur Bone regeneration membrane
US5353804A (en) 1990-09-18 1994-10-11 Peb Biopsy Corporation Method and device for percutaneous exisional breast biopsy
US5391183A (en) 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
US5108421A (en) 1990-10-01 1992-04-28 Quinton Instrument Company Insertion assembly and method of inserting a vessel plug into the body of a patient
US6347240B1 (en) 1990-10-19 2002-02-12 St. Louis University System and method for use in displaying images of a body part
US6325789B1 (en) 1990-12-27 2001-12-04 Datascope Investment Corporation Device and method for sealing puncture wounds
US5280788A (en) 1991-02-26 1994-01-25 Massachusetts Institute Of Technology Devices and methods for optical diagnosis of tissue
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
JP3007903B2 (en) 1991-03-29 2000-02-14 京セラ株式会社 Artificial disc
US5147631A (en) 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
US5242759A (en) 1991-05-21 1993-09-07 Cook Incorporated Joint, a laminate, and a method of preparing a nickel-titanium alloy member surface for bonding to another layer of metal
US5354623A (en) 1991-05-21 1994-10-11 Cook Incorporated Joint, a laminate, and a method of preparing a nickel-titanium alloy member surface for bonding to another layer of metal
CA2112905A1 (en) 1991-07-05 1993-01-21 Michael R. Violante Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5449560A (en) 1991-07-05 1995-09-12 Dow Corning S.A. Composition suitable for glass laminate interlayer and laminate made therefrom
US5195540A (en) 1991-08-12 1993-03-23 Samuel Shiber Lesion marking process
US5199441A (en) 1991-08-20 1993-04-06 Hogle Hugh H Fine needle aspiration biopsy apparatus and method
NL9101489A (en) 1991-09-03 1993-04-01 Texas Instruments Holland INJECTOR FOR IMMEDIATELY IMPLANTING AN OBJECT IN A LIVING BEING.
US5320100A (en) 1991-09-16 1994-06-14 Atrium Medical Corporation Implantable prosthetic device having integral patency diagnostic indicia
US5344640A (en) 1991-10-22 1994-09-06 Mallinckrodt Medical, Inc. Preparation of apatite particles for medical diagnostic imaging
US5290310A (en) 1991-10-30 1994-03-01 Howmedica, Inc. Hemostatic implant introducer
US5358514A (en) 1991-12-18 1994-10-25 Alfred E. Mann Foundation For Scientific Research Implantable microdevice with self-attaching electrodes
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
FR2686499A1 (en) 1992-01-28 1993-07-30 Technomed Int Sa APPARATUS FOR TREATING A TARGET, SUCH AS A DAMAGE WITHIN THE BODY OF A MAMMAL, PARTICULARLY A HUMAN BEING, USING A MARKING ELEMENT IMPLANTED IN OR IN THE VICINITY OF THE TARGET TO CONTROL THERAPY OF THE SAME TARGET.
AU682464B2 (en) 1992-03-06 1997-10-09 Lica Pharmaceuticals A/S Treatment and prophylaxis of diseases caused by parasites, or bacteria
IL104963A (en) 1992-03-06 1997-09-30 Nycomed Imaging As Contrast agents comprising methylene diester unit- containing biodegradable polymers
US6350274B1 (en) 1992-05-11 2002-02-26 Regen Biologics, Inc. Soft tissue closure systems
US5250026A (en) 1992-05-27 1993-10-05 Destron/Idi, Inc. Adjustable precision transponder injector
US5629008A (en) 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5366756A (en) 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
US5851461A (en) 1992-06-19 1998-12-22 Albany International Research Co. Method of producing polysaccharide foams
US5840777A (en) 1992-06-19 1998-11-24 Albany International Corp. Method of producing polysaccharide foams
US5281197A (en) 1992-07-27 1994-01-25 Symbiosis Corporation Endoscopic hemostatic agent delivery system
US5460182A (en) 1992-09-14 1995-10-24 Sextant Medical Corporation Tissue penetrating apparatus and methods
US5334216A (en) 1992-12-10 1994-08-02 Howmedica Inc. Hemostatic plug
US5320613A (en) 1993-01-06 1994-06-14 Scimed Life Systems, Inc. Medical lumen flushing and guide wire loading device and method
CA2153652A1 (en) 1993-01-12 1994-07-21 Se-Jin Lee Growth differentiation factor-3
JPH08500274A (en) 1993-01-19 1996-01-16 リー ハン−フー, Device and method for implant prosthesis
US5799099A (en) 1993-02-12 1998-08-25 George S. Allen Automatic technique for localizing externally attached fiducial markers in volume images of the head
US5730130A (en) 1993-02-12 1998-03-24 Johnson & Johnson Professional, Inc. Localization cap for fiducial markers
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
DE4306277C2 (en) 1993-03-01 2000-11-02 Leibinger Gmbh Operation marking tool
US5388588A (en) 1993-05-04 1995-02-14 Nabai; Hossein Biopsy wound closure device and method
US5312435A (en) 1993-05-17 1994-05-17 Kensey Nash Corporation Fail predictable, reinforced anchor for hemostatic puncture closure
US5409004A (en) 1993-06-11 1995-04-25 Cook Incorporated Localization device with radiopaque markings
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5431639A (en) 1993-08-12 1995-07-11 Boston Scientific Corporation Treating wounds caused by medical procedures
US5490521A (en) 1993-08-31 1996-02-13 Medtronic, Inc. Ultrasound biopsy needle
US5676698A (en) 1993-09-07 1997-10-14 Datascope Investment Corp. Soft tissue implant
US5360416A (en) 1993-09-30 1994-11-01 Sherwood Medical Company Thin-walled anesthesia needles
US5545180A (en) 1993-12-13 1996-08-13 Ethicon, Inc. Umbrella-shaped suture anchor device with actuating ring member
US5728122A (en) 1994-01-18 1998-03-17 Datascope Investment Corp. Guide wire with releaseable barb anchor
US6241734B1 (en) 1998-08-14 2001-06-05 Kyphon, Inc. Systems and methods for placing materials into bone
US5626611A (en) 1994-02-10 1997-05-06 United States Surgical Corporation Composite bioabsorbable materials and surgical articles made therefrom
US5928773A (en) 1994-02-15 1999-07-27 Vitric Corporation Foamed glass articles and methods of making same and methods of controlling the pH of same within specific limits
US5507807A (en) 1994-03-01 1996-04-16 Shippert; Ronald D. Apparatus for the release of a substance within a patient
US5417708A (en) 1994-03-09 1995-05-23 Cook Incorporated Intravascular treatment system and percutaneous release mechanism therefor
DE4424394B4 (en) 1994-07-13 2004-12-16 Bip Acquisition Company Inc., Wilmington Device for marking tissue sites
US6159445A (en) 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
DE69534233T2 (en) 1994-09-16 2005-10-27 Ethicon Endo-Surgery, Inc., Cincinnati DEVICES FOR DETERMINING AND MARKING TISSUE
US5954670A (en) 1994-10-05 1999-09-21 Baker; Gary H. Mandrel-guided tandem multiple channel biopsy guide device and method of use
US5891558A (en) 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
US5632432A (en) 1994-12-19 1997-05-27 Ethicon Endo-Surgery, Inc. Surgical instrument
US5499989A (en) 1994-12-22 1996-03-19 Labash; Stephen S. Breast biopsy apparatus and method of use
WO1996022123A1 (en) 1995-01-18 1996-07-25 Medchem Products, Inc. Apparatus and method for applying a hemostatic agent onto a tissue
US5657366A (en) 1995-02-23 1997-08-12 Nakayama; Masanari Film markers for specifying body postures of animal photographed in roentgenograms
FR2731343B1 (en) 1995-03-08 1997-08-22 De La Joliniere Jean H Bouquet DEVICE FOR LOCATING SUSPECTED BREAST INJURIES AND APPARATUS FOR PLACING SAME
US5795308A (en) 1995-03-09 1998-08-18 Russin; Lincoln D. Apparatus for coaxial breast biopsy
US5817022A (en) 1995-03-28 1998-10-06 Sonometrics Corporation System for displaying a 2-D ultrasound image within a 3-D viewing environment
US6135993A (en) 1995-04-17 2000-10-24 Hussman; Karl L. Optical localization fiber
US5782771A (en) 1995-04-17 1998-07-21 Hussman; Karl L. Dual, fused, and grooved optical localization fibers
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
GB2301362B (en) 1995-05-30 1999-01-06 Johnson & Johnson Medical Absorbable implant materials having controlled porosity
US5779647A (en) 1995-06-07 1998-07-14 Chau; Sonny Automated biopsy instruments
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5817034A (en) 1995-09-08 1998-10-06 United States Surgical Corporation Apparatus and method for removing tissue
US5611352A (en) 1995-09-14 1997-03-18 Kobren; Myles S. Cervical biopsy device
US6162192A (en) 1998-05-01 2000-12-19 Sub Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
DE69633411T2 (en) 1995-10-13 2005-10-20 Transvascular, Inc., Menlo Park METHOD AND DEVICE FOR PREVENTING ARTERIAL ATTRACTIONS AND / OR FOR CARRYING OUT OTHER TRANSVASCULAR INTERVENTIONS
EP0955933B1 (en) 1995-10-13 2009-08-26 Medtronic Vascular, Inc. A device for interstitial transvascular intervention
CA2187975C (en) 1995-10-20 2001-05-01 Lisa W. Heaton Surgical apparatus and method for marking tissue location
US5800445A (en) 1995-10-20 1998-09-01 United States Surgical Corporation Tissue tagging device
US5782764A (en) 1995-11-07 1998-07-21 Iti Medical Technologies, Inc. Fiber composite invasive medical instruments and methods for use in interventional imaging procedures
US5702682A (en) 1995-12-01 1997-12-30 Hercules Incorporated Methods for preparing radiopaque medical devices
US5769086A (en) 1995-12-06 1998-06-23 Biopsys Medical, Inc. Control system and method for automated biopsy device
US5752974A (en) 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US5800389A (en) 1996-02-09 1998-09-01 Emx, Inc. Biopsy device
US6203524B1 (en) 1997-02-10 2001-03-20 Emx, Inc. Surgical and pharmaceutical site access guide and methods
US5842477A (en) 1996-02-21 1998-12-01 Advanced Tissue Sciences, Inc. Method for repairing cartilage
US5821184A (en) 1996-03-29 1998-10-13 Andrew Ungerleider Foamed glass article for preparing surfaces, use therefor, and method of making same
US5865806A (en) 1996-04-04 1999-02-02 Becton Dickinson And Company One step catheter advancement automatic needle retraction system
US5824042A (en) 1996-04-05 1998-10-20 Medtronic, Inc. Endoluminal prostheses having position indicating markers
US5669882A (en) 1996-04-23 1997-09-23 Pyles; Stephen Curved epidural needle system
US7236816B2 (en) 1996-04-25 2007-06-26 Johns Hopkins University Biopsy and sampling needle antennas for magnetic resonance imaging-guided biopsies
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6530896B1 (en) 1996-05-13 2003-03-11 James B. Elliott Apparatus and method for introducing an implant
US5690120A (en) 1996-05-24 1997-11-25 Sarcos, Inc. Hybrid catheter guide wire apparatus
US5820918A (en) 1996-07-11 1998-10-13 Hercules Incorporated Medical devices containing in-situ generated medical compounds
US5702128A (en) 1996-07-18 1997-12-30 Beekley Corporation Radiographic marker system and method of making same
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US5842999A (en) 1996-07-31 1998-12-01 C.R. Bard, Inc. Automated tissue sampling device
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5810884A (en) 1996-09-09 1998-09-22 Beth Israel Deaconess Medical Center Apparatus and method for closing a vascular perforation after percutaneous puncture of a blood vessel in a living subject
US5824081A (en) 1996-09-13 1998-10-20 Lipomatrix Incorporated Hydraulic foam tissue implant
US6166079A (en) 1996-09-25 2000-12-26 Board Of Regents, The University Of Texas System DFMO for the treatment or prevention of cervical intraepithelial neoplasia
ATE318618T1 (en) 1996-10-28 2006-03-15 Amersham Health As IMPROVEMENTS IN OR RELATED TO DIAGNOSTIC/THERAPEUTIC COMPOUNDS
US5845646A (en) 1996-11-05 1998-12-08 Lemelson; Jerome System and method for treating select tissue in a living being
US6106473A (en) 1996-11-06 2000-08-22 Sts Biopolymers, Inc. Echogenic coatings
US6119031A (en) 1996-11-21 2000-09-12 Boston Scientific Corporation Miniature spectrometer
US5897507A (en) 1996-11-25 1999-04-27 Symbiosis Corporation Biopsy forceps instrument having irrigation and aspiration capabilities
US5718916A (en) 1997-02-03 1998-02-17 Scherr; George H. Alginate foam products
US5876340A (en) 1997-04-17 1999-03-02 Irvine Biomedical, Inc. Ablation apparatus with ultrasonic imaging capabilities
US5941439A (en) 1997-05-14 1999-08-24 Mitek Surgical Products, Inc. Applicator and method for deploying a surgical fastener in tissue
US5876457A (en) 1997-05-20 1999-03-02 George J. Picha Spinal implant
JP2002503991A (en) 1997-06-13 2002-02-05 マイクロ・テラピューティクス・インコーポレーテッド Syringe and luer hub having novel shape and method of forming embolus
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
US6306154B1 (en) 1997-06-18 2001-10-23 Bhk Holding Hemostatic system for body cavities
US5976146A (en) 1997-07-11 1999-11-02 Olympus Optical Co., Ltd. Surgical operation system and method of securing working space for surgical operation in body
DE19731021A1 (en) 1997-07-18 1999-01-21 Meyer Joerg In vivo degradable metallic implant
US6096037A (en) 1997-07-29 2000-08-01 Medtronic, Inc. Tissue sealing electrosurgery device and methods of sealing tissue
US6096065A (en) 1997-09-29 2000-08-01 Boston Scientific Corporation Sheath for tissue spectroscopy
US6174330B1 (en) 1997-08-01 2001-01-16 Schneider (Usa) Inc Bioabsorbable marker having radiopaque constituents
US5980564A (en) 1997-08-01 1999-11-09 Schneider (Usa) Inc. Bioabsorbable implantable endoprosthesis with reservoir
US6340367B1 (en) 1997-08-01 2002-01-22 Boston Scientific Scimed, Inc. Radiopaque markers and methods of using the same
US6090996A (en) 1997-08-04 2000-07-18 Collagen Matrix, Inc. Implant matrix
AU8772198A (en) 1997-08-05 1999-03-08 Target Therapeutics, Inc. Detachable aneurysm neck bridge
US5854382A (en) 1997-08-18 1998-12-29 Meadox Medicals, Inc. Bioresorbable compositions for implantable prostheses
DE20103363U1 (en) 2001-02-26 2001-05-17 Braun Melsungen Ag Protection device for an injection needle
US7125397B2 (en) 1997-08-20 2006-10-24 B. Braun Melsungen Ag Protective device for an injection needle
US6117108A (en) 1997-08-20 2000-09-12 Braun Melsungen Ag Spring clip safety IV catheter
US6616630B1 (en) 1997-08-20 2003-09-09 B. Braun Melsungen A.G. Spring clip safety IV catheter
EP1009317A4 (en) 1997-08-28 2001-01-24 Boston Scient Corp System for implanting a cross-linked polysaccharide fiber and methods of forming and inserting the fiber
US6551253B2 (en) 1997-09-12 2003-04-22 Imagyn Medical Technologies Incisional breast biopsy device
US6142955A (en) 1997-09-19 2000-11-07 United States Surgical Corporation Biopsy apparatus and method
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US8288745B2 (en) 1997-10-10 2012-10-16 Senorx, Inc. Method of utilizing an implant for targeting external beam radiation
US6638308B2 (en) 1997-10-10 2003-10-28 John D. Corbitt, Jr. Bioabsorbable breast implant
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
WO1999018886A1 (en) 1997-10-10 1999-04-22 Corbitt John D Jr Breast implant
US6511468B1 (en) 1997-10-17 2003-01-28 Micro Therapeutics, Inc. Device and method for controlling injection of liquid embolic composition
US6030333A (en) 1997-10-24 2000-02-29 Radiomed Corporation Implantable radiotherapy device
WO1999021584A1 (en) 1997-10-24 1999-05-06 Children's Medical Center Corporation METHODS FOR PROMOTING CELL TRANSFECTION $i(IN VIVO)
US6419621B1 (en) 1997-10-24 2002-07-16 Radiomed Corporation Coiled brachytherapy device
PT1044032E (en) 1997-12-29 2004-08-31 Alza Corp IMPLANTING DEVICE FOR SEBCUTANEOUS IMPLANTS
US6451871B1 (en) 1998-11-25 2002-09-17 Novartis Ag Methods of modifying surface characteristics
US6118848A (en) 1998-01-14 2000-09-12 Reiffel; Leonard System to stabilize an irradiated internal target
US6181960B1 (en) 1998-01-15 2001-01-30 University Of Virginia Patent Foundation Biopsy marker device
US6289229B1 (en) 1998-01-20 2001-09-11 Scimed Life Systems, Inc. Readable probe array for in vivo use
US6660010B2 (en) 1998-01-27 2003-12-09 Scimed Life Systems, Inc. Bone anchor placement device with recessed anchor mount
US6540693B2 (en) 1998-03-03 2003-04-01 Senorx, Inc. Methods and apparatus for securing medical instruments to desired locations in a patients body
US6053925A (en) 1998-02-27 2000-04-25 Barnhart; William H. Lesion localization device and method
US6471700B1 (en) 1998-04-08 2002-10-29 Senorx, Inc. Apparatus and method for accessing biopsy site
US6312429B1 (en) 1998-09-01 2001-11-06 Senorx, Inc. Electrosurgical lesion location device
US6638234B2 (en) 1998-03-03 2003-10-28 Senorx, Inc. Sentinel node location and biopsy
US6447527B1 (en) 1998-04-23 2002-09-10 Ronald J. Thompson Apparatus and methods for the penetration of tissue
US6610026B2 (en) 1998-05-01 2003-08-26 Sub-Q, Inc. Method of hydrating a sponge material for delivery to a body
US20010045575A1 (en) 1998-05-01 2001-11-29 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US6363940B1 (en) 1998-05-14 2002-04-02 Calypso Medical Technologies, Inc. System and method for bracketing and removing tissue
US6224630B1 (en) 1998-05-29 2001-05-01 Advanced Bio Surfaces, Inc. Implantable tissue repair device
US20020058882A1 (en) 1998-06-22 2002-05-16 Artemis Medical, Incorporated Biopsy localization method and device
EP0966979B1 (en) 1998-06-25 2006-03-08 Biotronik AG Implantable bioresorbable support for the vascular walls, in particular coronary stent
US6261302B1 (en) 1998-06-26 2001-07-17 Ethicon Endo-Surgery, Inc. Applier for implantable surgical marker
US5941890A (en) 1998-06-26 1999-08-24 Ethicon Endo-Surgery, Inc. Implantable surgical marker
US5921933A (en) 1998-08-17 1999-07-13 Medtronic, Inc. Medical devices with echogenic coatings
US6179860B1 (en) 1998-08-19 2001-01-30 Artemis Medical, Inc. Target tissue localization device and method
IL141462A0 (en) 1998-08-21 2002-03-10 Providence Health Sys Oregon Insertable stent and methods of making and using the same
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6159240A (en) 1998-08-31 2000-12-12 Medtronic, Inc. Rigid annuloplasty device that becomes compliant after implantation
US6936014B2 (en) 2002-10-16 2005-08-30 Rubicor Medical, Inc. Devices and methods for performing procedures on a breast
US6656192B2 (en) 1998-09-25 2003-12-02 United States Surgical Corporatioin Site marker device
WO2000019979A1 (en) 1998-10-07 2000-04-13 Giltech Limited Foamable formulation and foam
US6056700A (en) 1998-10-13 2000-05-02 Emx, Inc. Biopsy marker assembly and method of use
DE69931006T2 (en) 1998-10-14 2007-01-04 Terumo K.K. Wired radiation source and catheter assembly for radiotherapy
US6220248B1 (en) 1998-10-21 2001-04-24 Ethicon Endo-Surgery, Inc. Method for implanting a biopsy marker
WO2000023124A1 (en) 1998-10-22 2000-04-27 Edwards Lifesciences Corporation Multi-functional coatings for medical devices
US6951564B2 (en) 1998-10-23 2005-10-04 United States Surgical Corporation Site marker device
AU1126500A (en) 1998-10-23 2000-05-15 Armand F. Cortese Marker for indicating the location of identified tissue
US7844319B2 (en) 1998-11-04 2010-11-30 Susil Robert C Systems and methods for magnetic-resonance-guided interventional procedures
DE69930140T2 (en) 1998-11-06 2006-11-23 Ge Healthcare Ltd., Little Chalfont DEVICES AND METHODS FOR BRACHYTHERAPY
US6270472B1 (en) 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US7189206B2 (en) 2003-02-24 2007-03-13 Senorx, Inc. Biopsy device with inner cutter
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
JP3720999B2 (en) 1999-02-18 2005-11-30 沖電気工業株式会社 Input protection circuit
US6482143B1 (en) 1999-02-28 2002-11-19 Syntheon, Llc Raidoactive therapeutic seed having selective marker configuration
US6200258B1 (en) 1999-08-10 2001-03-13 Syntheon, Llc Radioactive therapeutic seed having selective marker configuration
US6173715B1 (en) 1999-03-01 2001-01-16 Lucent Medical Systems, Inc. Magnetic anatomical marker and method of use
US6203507B1 (en) 1999-03-03 2001-03-20 Cordis Webster, Inc. Deflectable catheter with ergonomic handle
US6144875A (en) 1999-03-16 2000-11-07 Accuray Incorporated Apparatus and method for compensating for respiratory and patient motion during treatment
AU776009B2 (en) 1999-04-09 2004-08-26 Regents Of The University Of Michigan, The Preparing porous hydrogel products
GB9909801D0 (en) 1999-04-28 1999-06-23 Btg Int Ltd Ultrasound detectable instrument
US6712836B1 (en) 1999-05-13 2004-03-30 St. Jude Medical Atg, Inc. Apparatus and methods for closing septal defects and occluding blood flow
US20060247665A1 (en) 1999-05-28 2006-11-02 Ferree Bret A Methods and apparatus for treating disc herniation and preventing the extrusion of interbody bone graft
WO2000074565A1 (en) 1999-06-05 2000-12-14 Wilson-Cook Medical Inc. Indicia for an endoscopic medical device
US6066122A (en) 1999-06-09 2000-05-23 Fisher; John Needle apparatus and method for marking lesions
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
US6626899B2 (en) 1999-06-25 2003-09-30 Nidus Medical, Llc Apparatus and methods for treating tissue
US6333029B1 (en) 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
WO2001008578A1 (en) 1999-07-30 2001-02-08 Vivant Medical, Inc. Device and method for safe location and marking of a cavity and sentinel lymph nodes
US6234177B1 (en) 1999-08-12 2001-05-22 Thomas Barsch Apparatus and method for deploying an expandable biopsy marker
US6250307B1 (en) 1999-09-17 2001-06-26 Pi Medical, Inc. Snoring treatment
JP2001161838A (en) 1999-12-07 2001-06-19 Radiomed Corp Wire-like radiation source member for cancer treatment and feeding device of the same
AU2623201A (en) 1999-12-30 2001-07-16 Kam W Leong Controlled delivery of therapeutic agents by insertable medical devices
EP1114618A3 (en) 2000-01-04 2001-08-22 Ethicon Endo-Surgery, Inc. Surgical instrument for applying beads to tissue
US6506156B1 (en) 2000-01-19 2003-01-14 Vascular Control Systems, Inc Echogenic coating
US6575888B2 (en) 2000-01-25 2003-06-10 Biosurface Engineering Technologies, Inc. Bioabsorbable brachytherapy device
BR0104246A (en) 2000-01-26 2002-05-21 Heartport Inc Vascular incisor and method
US6436030B2 (en) 2000-01-31 2002-08-20 Om P. Rehil Hiatal hernia repair patch and method for using the same
US6358217B1 (en) 2000-01-31 2002-03-19 Hugh Bourassa Automatic and semi-automatic disposable biopsy needle device
US6564806B1 (en) 2000-02-18 2003-05-20 Thomas J. Fogarty Device for accurately marking tissue
US6241687B1 (en) 2000-02-18 2001-06-05 Ethicon Endo-Surgery, Inc. Method of use for a biopsy instrument with breakable sample segments
JP5090600B2 (en) 2000-02-18 2012-12-05 トーマス ジェイ. フォガーティー, Improved device for accurately marking tissues
US6770070B1 (en) 2000-03-17 2004-08-03 Rita Medical Systems, Inc. Lung treatment apparatus and method
US6450938B1 (en) 2000-03-21 2002-09-17 Promex, Llc Brachytherapy device
US6356112B1 (en) 2000-03-28 2002-03-12 Translogic Technology, Inc. Exclusive or/nor circuit
US6628982B1 (en) 2000-03-30 2003-09-30 The Regents Of The University Of Michigan Internal marker device for identification of biological substances
NZ522128A (en) 2000-03-31 2003-08-29 Rita Medical Systems Inc Tissue biopsy and treatment apparatus and method
US6425903B1 (en) 2000-05-09 2002-07-30 James W. Voegele Implantable surgical marker
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US7419678B2 (en) 2000-05-12 2008-09-02 Cordis Corporation Coated medical devices for the prevention and treatment of vascular disease
US6544231B1 (en) 2000-05-22 2003-04-08 Medcanica, Inc. Catch, stop and marker assembly for a medical instrument and medical instrument incorporating the same
US20020044969A1 (en) 2000-05-22 2002-04-18 Jerome Harden Method for increasing the compressibility of poorly binding powder materials
US6961608B2 (en) 2000-06-05 2005-11-01 Kabushiki Kaisha Toshiba Interventional MR imaging with detection and display of device position
US6991652B2 (en) 2000-06-13 2006-01-31 Burg Karen J L Tissue engineering composite
US6280514B1 (en) 2000-06-23 2001-08-28 National Starch And Chemical Investment Holding Corporation Process for making a foamed polysaccharide aqueous-based adhesive
US20020077693A1 (en) 2000-12-19 2002-06-20 Barclay Bruce J. Covered, coiled drug delivery stent and method
WO2002013713A1 (en) 2000-08-10 2002-02-21 Cook Incorporated Localizer needle
WO2002024114A2 (en) 2000-09-25 2002-03-28 Cohesion Technologies, Inc. Resorbable anastomosis stents and plugs
US6716444B1 (en) 2000-09-28 2004-04-06 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US7261735B2 (en) 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US6863685B2 (en) 2001-03-29 2005-03-08 Cordis Corporation Radiopacity intraluminal medical device
US6712774B2 (en) 2000-10-13 2004-03-30 James W. Voegele Lockout for a surgical biopsy device
US6730044B2 (en) 2000-10-13 2004-05-04 Ethicon Endo-Surgery, Inc. Firing mechanism for use in a surgical biopsy device
US6540694B1 (en) 2000-10-16 2003-04-01 Sanarus Medical, Inc. Device for biopsy tumors
US6447524B1 (en) 2000-10-19 2002-09-10 Ethicon Endo-Surgery, Inc. Fastener for hernia mesh fixation
US6544185B2 (en) 2000-10-23 2003-04-08 Valentino Montegrande Ultrasound imaging marker and method of use
EP1377342A4 (en) 2000-10-25 2006-11-29 Gary A Lamoureux Pre-loaded needle assembly
US6918927B2 (en) 2000-10-31 2005-07-19 Cook Incorporated Coated implantable medical device
US6758824B1 (en) 2000-11-06 2004-07-06 Suros Surgical Systems, Inc. Biopsy apparatus
US6514193B2 (en) 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
AU2002239290A1 (en) 2000-11-20 2002-06-03 Senorx, Inc. Tissue site markers for in vivo imaging
US20020077687A1 (en) 2000-12-14 2002-06-20 Ahn Samuel S. Catheter assembly for treating ischemic tissue
US6478790B2 (en) 2000-12-22 2002-11-12 Frank M. Bardani Implant device and dosage form employable therein
WO2002054941A2 (en) 2001-01-11 2002-07-18 Rita Medical Systems Inc Bone-treatment instrument and method
US6749627B2 (en) 2001-01-18 2004-06-15 Ev3 Peripheral, Inc. Grip for stent delivery system
US7014610B2 (en) 2001-02-09 2006-03-21 Medtronic, Inc. Echogenic devices and methods of making and using such devices
US6636758B2 (en) 2001-05-01 2003-10-21 Concentric Medical, Inc. Marker wire and process for using it
US6824527B2 (en) 2001-06-07 2004-11-30 Peter Gollobin Protective sheath for winged needles and sheath and needle assembly
US6723052B2 (en) 2001-06-07 2004-04-20 Stanley L. Mills Echogenic medical device
US8197535B2 (en) 2001-06-19 2012-06-12 Cordis Corporation Low profile improved radiopacity intraluminal medical device
US7160258B2 (en) 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
US6648849B2 (en) 2001-06-27 2003-11-18 Ethicon, Inc. Medicinal implant and device and method for loading and delivering implants containing drugs and cells
ATE294535T1 (en) 2001-07-26 2005-05-15 Univ Oregon Health Sciences CLOSURE DEVICE FOR A VESSEL AND ATTACHMENT DEVICE
JP4166691B2 (en) 2001-08-03 2008-10-15 タイコ ヘルスケア グループ エルピー Tissue marking apparatus and method
US6913626B2 (en) 2001-08-14 2005-07-05 Mcghan Jim J. Medical implant having bioabsorbable textured surface
US7135978B2 (en) 2001-09-14 2006-11-14 Calypso Medical Technologies, Inc. Miniature resonating marker assembly
US7294118B2 (en) 2001-10-24 2007-11-13 Becton, Dickinson And Company Retractable needle assembly
US6939318B2 (en) 2002-05-03 2005-09-06 Boston Scientific Scimed, Inc. Method, tool, and system for deploying an implant into the body
US7280865B2 (en) 2001-12-20 2007-10-09 Accuray Incorporated Anchored fiducial apparatus and method
US20030225420A1 (en) 2002-03-11 2003-12-04 Wardle John L. Surgical coils and methods of deploying
US7527610B2 (en) 2002-03-29 2009-05-05 Bioform Medical, Inc. Connection indicator for a medical delivery/extraction system
AU2003230807B2 (en) 2002-04-03 2008-03-13 Medarex, Inc. Use of biomolecular targets in the treatment and visualization of brain tumors
US20030191355A1 (en) 2002-04-04 2003-10-09 Ferguson Patrick J. Hollow bioabsorbable elements for positioning material in living tissue
US6818668B2 (en) 2002-04-12 2004-11-16 Biotest Laboratories, Llc 5-alkyl-7-alkylcarbonate-isoflavone ester and related method
US20030199887A1 (en) 2002-04-23 2003-10-23 David Ferrera Filamentous embolization device and method of use
US6652442B2 (en) 2002-04-23 2003-11-25 Acueity, Inc. Micro-endoscope assembly for intraductal brachytherapy of a mammary duct and method of using same
US7329414B2 (en) 2002-05-03 2008-02-12 Biopsy Sciences, Llc Biodegradable polymer for marking tissue and sealing tracts
US6780179B2 (en) 2002-05-22 2004-08-24 Rubicor Medical, Inc. Methods and systems for in situ tissue marking and orientation stabilization
US6992233B2 (en) 2002-05-31 2006-01-31 Medafor, Inc. Material delivery system
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US20040101548A1 (en) 2002-11-26 2004-05-27 Pendharkar Sanyog Manohar Hemostatic wound dressing containing aldehyde-modified polysaccharide
ATE495769T1 (en) 2002-07-12 2011-02-15 Cook Inc COATED MEDICAL DEVICE
US20040016195A1 (en) 2002-07-24 2004-01-29 Archuleta John Paul Foamed glass article for use as thermal energy control media
WO2004012600A2 (en) 2002-08-01 2004-02-12 Selis James E Biopsy devices
AU2003262988A1 (en) 2002-08-30 2004-03-19 Inrad, Inc. Localizing needle with fluid delivery
US7103418B2 (en) 2002-10-02 2006-09-05 Medtronic, Inc. Active fluid delivery catheter
US7041047B2 (en) 2002-10-04 2006-05-09 Boston Scientific Scimed, Inc. Method and apparatus for the delivery of brachytherapy
US20040116802A1 (en) 2002-10-05 2004-06-17 Jessop Precision Products, Inc. Medical imaging marker
US8027712B2 (en) 2002-10-11 2011-09-27 Ion Beam Applications S.A. Elongated markers for soft tissue volume identification
US6994712B1 (en) 2002-11-12 2006-02-07 Biopsy Sciences, Llc Bioabsorbable marker having external anchoring means
AU2003290918A1 (en) 2002-11-18 2004-06-15 Chesbrough, Richard, M. Tissue localizing and marking device and method of using same
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
US7008382B2 (en) 2002-11-20 2006-03-07 Scimed Life Systems, Inc. Medical instrument
US8137288B2 (en) 2002-11-20 2012-03-20 Boston Scientific Scimed, Inc. Medical instrument
US7247160B2 (en) 2002-12-30 2007-07-24 Calypso Medical Technologies, Inc. Apparatuses and methods for percutaneously implanting objects in patients
US6889833B2 (en) 2002-12-30 2005-05-10 Calypso Medical Technologies, Inc. Packaged systems for implanting markers in a patient and methods for manufacturing and using such systems
US20040133124A1 (en) 2003-01-06 2004-07-08 Cook Incorporated. Flexible biopsy needle
US9314235B2 (en) 2003-02-05 2016-04-19 Smith & Nephew, Inc. Tissue anchor and insertion tool
WO2004075789A2 (en) 2003-02-26 2004-09-10 Cook Incorporated PROTHESIS ADAPTED FOR PLACEDd UNDER EXTERNAL IMAGING
FR2853521B1 (en) 2003-04-10 2005-12-02 Claude Mialhe DEVICE FOR EXPANDING A VESSEL AND INTRODUCING VASCULAR IMPLANT
US8372112B2 (en) 2003-04-11 2013-02-12 St. Jude Medical, Cardiology Division, Inc. Closure devices, related delivery methods, and related methods of use
US7306580B2 (en) 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
DE10318802A1 (en) 2003-04-17 2004-11-04 Aesculap Ag & Co. Kg Self-adhesive, resorbable hemostatic
CA2523246C (en) 2003-04-25 2009-12-01 Kos Life Sciences, Inc. Formation of strong superporous hydrogels
US6945973B2 (en) 2003-05-01 2005-09-20 Nuvasive, Inc. Slidable bone plate system
US20050119562A1 (en) 2003-05-23 2005-06-02 Senorx, Inc. Fibrous marker formed of synthetic polymer strands
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US7783336B2 (en) 2003-06-06 2010-08-24 Ethicon Endo-Surgery, Inc. Subcutaneous biopsy cavity marker device
US20040265371A1 (en) 2003-06-25 2004-12-30 Looney Dwayne Lee Hemostatic devices and methods of making same
US7744852B2 (en) 2003-07-25 2010-06-29 Rubicor Medical, Llc Methods and systems for marking post biopsy cavity sites
US20050033157A1 (en) 2003-07-25 2005-02-10 Klein Dean A. Multi-modality marking material and method
US7537788B2 (en) 2003-07-25 2009-05-26 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US20050049634A1 (en) 2003-08-07 2005-03-03 Scimed Life Systems, Inc. Medical closure device
US7790141B2 (en) 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US7001341B2 (en) 2003-08-13 2006-02-21 Scimed Life Systems, Inc. Marking biopsy sites
DE602004025824D1 (en) 2003-09-08 2010-04-15 Fmc Biopolymer As GEL FOAM ON BIOPOLYMER BASE
US20050059887A1 (en) 2003-09-16 2005-03-17 Hassan Mostafavi Localization of a target using in vivo markers
WO2005037338A1 (en) 2003-10-14 2005-04-28 Cook Incorporated Hydrophilic coated medical device
WO2005065079A2 (en) 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
EP1689308A1 (en) 2003-11-26 2006-08-16 Invivo Germany GmbH Tissue marker and method and apparatus for deploying the marker
US20050113659A1 (en) 2003-11-26 2005-05-26 Albert Pothier Device for data input for surgical navigation system
US20050142161A1 (en) 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
US7761138B2 (en) 2004-03-12 2010-07-20 Boston Scientific Scimed, Inc. MRI and X-ray visualization
US7901707B2 (en) 2004-03-15 2011-03-08 Christine Allen Biodegradable biocompatible implant and method of manufacturing same
US20050234336A1 (en) 2004-03-26 2005-10-20 Beckman Andrew T Apparatus and method for marking tissue
US7959634B2 (en) 2004-03-29 2011-06-14 Soteira Inc. Orthopedic surgery access devices
ES2638301T3 (en) 2004-05-14 2017-10-19 Ethicon Llc Suture devices
US9638770B2 (en) 2004-05-21 2017-05-02 Devicor Medical Products, Inc. MRI biopsy apparatus incorporating an imageable penetrating portion
US8075568B2 (en) 2004-06-11 2011-12-13 Selis James E Biopsy devices and methods
DE102004030391A1 (en) 2004-06-23 2006-01-26 Somatex Medical Technologies Gmbh marker
WO2006022786A1 (en) 2004-08-20 2006-03-02 David Mullen Tissue marking devices and systems
US20060079805A1 (en) 2004-10-13 2006-04-13 Miller Michael E Site marker visable under multiple modalities
US8280486B2 (en) 2004-10-13 2012-10-02 Suros Surgical Systems, Inc. Site marker visable under multiple modalities
EP1806160A1 (en) 2004-10-22 2007-07-11 Kaneka Corporation Catheter for medical treatment
WO2006056739A2 (en) 2004-11-23 2006-06-01 Quantum Medical Technology Limited Surgical tag, magnetometer, and associated system
KR20070104574A (en) 2004-12-30 2007-10-26 신벤션 아게 Combination comprising an agent providing a signal, an implant material and a drug
DE102005012574A1 (en) 2005-03-18 2006-09-21 Bkh - Technotransfer Gmbh Markers for animal and human tissue, in particular soft tissue
US20060217635A1 (en) 2005-03-24 2006-09-28 Mccombs Elizabeth S Biopsy device marker deployment
US20060235298A1 (en) 2005-03-31 2006-10-19 Robert Kotmel Internal biopsy marking
US20060241385A1 (en) 2005-04-12 2006-10-26 Ethicon Endo-Surgery, Inc. Guided disposable fiducial for breast biopsy localization fixture
JP5249754B2 (en) 2005-06-21 2013-07-31 ナヴィスカン ペット システムズ,インコーポレーテッド Tissue intervention using nuclear radiation tomographic guidance
US20060292690A1 (en) 2005-06-22 2006-12-28 Cesco Bioengineering Co., Ltd. Method of making cell growth surface
US7736293B2 (en) 2005-07-22 2010-06-15 Biocompatibles Uk Limited Implants for use in brachytherapy and other radiation therapy that resist migration and rotation
US9498647B2 (en) 2005-09-23 2016-11-22 Allen B. Kantrowitz Fiducial marker system for subject movement compensation during medical treatment
EP1767167B1 (en) 2005-09-26 2011-05-18 Bard Peripheral Vascular, Inc. Post decompression marker introducer system
US20070083132A1 (en) 2005-10-11 2007-04-12 Sharrow James S Medical device coil
US7761137B2 (en) 2005-12-16 2010-07-20 Suros Surgical Systems, Inc. Biopsy site marker deployment device
AU2007224137A1 (en) 2006-03-01 2007-09-13 Fmc Biopolymer As Biodegradable foam
US8118786B2 (en) 2006-03-29 2012-02-21 Kawasumi Laboratories, Inc. Guarded medical winged needle assembly
US20070287933A1 (en) 2006-06-08 2007-12-13 Chris Phan Tissue debulking device and method of using the same
US20090171198A1 (en) 2006-08-04 2009-07-02 Jones Michael L Powdered marker
US7945307B2 (en) 2006-08-04 2011-05-17 Senorx, Inc. Marker delivery system with obturator
US8064987B2 (en) 2006-10-23 2011-11-22 C. R. Bard, Inc. Breast marker
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
US20080177179A1 (en) 2006-12-19 2008-07-24 Cytyc Corporation Target Tissue Locator for Image Guided Radiotherapy
US20090024225A1 (en) 2007-07-16 2009-01-22 Stubbs James B Implant for Targeting Therapeutic Procedure
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant

Patent Citations (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2192270A (en) * 1938-05-25 1940-03-05 American Brake Co Brake rigging
US3341417A (en) * 1965-07-14 1967-09-12 Edwin S Sinaiko Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators
US3823212A (en) * 1968-11-27 1974-07-09 Freudenberg C Fa Process for the production of collagen fiber fabrics in the form of felt-like membranes or sponge-like layers
US3818894A (en) * 1971-01-22 1974-06-25 Ceskoslovenska Akademie Ved Laryngeal implant
US4197846A (en) * 1974-10-09 1980-04-15 Louis Bucalo Method for structure for situating in a living body agents for treating the body
US4007732A (en) * 1975-09-02 1977-02-15 Robert Carl Kvavle Method for location and removal of soft tissue in human biopsy operations
US4294241A (en) * 1977-06-09 1981-10-13 Teruo Miyata Collagen skin dressing
US4172449A (en) * 1978-05-01 1979-10-30 New Research And Development Laboratories, Inc. Body fluid pressure monitor
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4545367A (en) * 1982-07-16 1985-10-08 Cordis Corporation Detachable balloon catheter and method of use
US4647480A (en) * 1983-07-25 1987-03-03 Amchem Products, Inc. Use of additive in aqueous cure of autodeposited coatings
US4863470A (en) * 1985-03-19 1989-09-05 Medical Engineering Corporation Identification marker for a breast prosthesis
US4847049A (en) * 1985-12-18 1989-07-11 Vitaphore Corporation Method of forming chelated collagen having bactericidal properties
US4693237A (en) * 1986-01-21 1987-09-15 Hoffman Richard B Radiopaque coded ring markers for use in identifying surgical grafts
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4813062A (en) * 1986-08-13 1989-03-14 Milliken Research Corporation Radio-opaque marker and method
US4889707A (en) * 1988-01-29 1989-12-26 The Curators Of The University Of Missouri Composition and method for radiation synovectomy of arthritic joints
US4938763A (en) * 1988-10-03 1990-07-03 Dunn Richard L Biodegradable in-situ forming implants and methods of producing the same
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4909250A (en) * 1988-11-14 1990-03-20 Smith Joseph R Implant system for animal identification
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5137928A (en) * 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5236410A (en) * 1990-08-02 1993-08-17 Ferrotherm International, Inc. Tumor treatment method
US5221269A (en) * 1990-10-15 1993-06-22 Cook Incorporated Guide for localizing a nonpalpable breast lesion
US5282781A (en) * 1990-10-25 1994-02-01 Omnitron International Inc. Source wire for localized radiation treatment of tumors
US5688490A (en) * 1991-02-15 1997-11-18 Bracco International B.V. Mucoadhesive compositions for increasing the ultrasonic image contrast of the digestive tract
US5395319A (en) * 1991-03-06 1995-03-07 Suddeutsche Feinmechanik Gmbh Needle for inserting an object into the body
US5281408A (en) * 1991-04-05 1994-01-25 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5147307A (en) * 1991-06-17 1992-09-15 Gluck Seymour M Anatomical marker device and method
US5538726A (en) * 1992-02-28 1996-07-23 Order; Stanley E. Method and compositions for delivering cytotoxic agents to cancer
US5676925A (en) * 1992-03-06 1997-10-14 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5549560A (en) * 1992-05-13 1996-08-27 Wijdeven Gijsbertus G P Van De Apparatus and method for injecting a pharmaceutical preparation in solid form
US5469847A (en) * 1992-09-09 1995-11-28 Izi Corporation Radiographic multi-modality skin markers
US5368030A (en) * 1992-09-09 1994-11-29 Izi Corporation Non-invasive multi-modality radiographic surface markers
US5646146A (en) * 1993-02-02 1997-07-08 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
US5394875A (en) * 1993-10-21 1995-03-07 Lewis; Judith T. Automatic ultrasonic localization of targets implanted in a portion of the anatomy
US5433204A (en) * 1993-11-16 1995-07-18 Camilla Olson Method of assessing placentation
US5422730A (en) * 1994-03-25 1995-06-06 Barlow; Clyde H. Automated optical detection of tissue perfusion by microspheres
US5451406A (en) * 1994-07-14 1995-09-19 Advanced Uroscience, Inc. Tissue injectable composition and method of use
US5643246A (en) * 1995-02-24 1997-07-01 Gel Sciences, Inc. Electromagnetically triggered, responsive gel based drug delivery device
US5762903A (en) * 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
US5580568A (en) * 1995-07-27 1996-12-03 Micro Therapeutics, Inc. Cellulose diacetate compositions for use in embolizing blood vessels
US5667767A (en) * 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5851508A (en) * 1995-07-27 1998-12-22 Microtherapeutics, Inc. Compositions for use in embolizing blood vessels
US5782775A (en) * 1995-10-20 1998-07-21 United States Surgical Corporation Apparatus and method for localizing and removing tissue
US5636255A (en) * 1996-03-05 1997-06-03 Queen's University At Kingston Method and apparatus for CT image registration
US5942209A (en) * 1996-03-11 1999-08-24 Focal, Inc. Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel
US20010006616A1 (en) * 1996-03-11 2001-07-05 Leavitt Richard D Polymeric delivery of radionuclides and radiopharmaceuticals
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
US5853366A (en) * 1996-07-08 1998-12-29 Kelsey, Inc. Marker element for interstitial treatment and localizing device and method using same
US5695480A (en) * 1996-07-29 1997-12-09 Micro Therapeutics, Inc. Embolizing compositions
US5823198A (en) * 1996-07-31 1998-10-20 Micro Therapeutics, Inc. Method and apparatus for intravasculer embolization
US5902310A (en) * 1996-08-12 1999-05-11 Ethicon Endo-Surgery, Inc. Apparatus and method for marking tissue
US5676146B1 (en) * 1996-09-13 2000-04-18 Osteotech Inc Surgical implant containing a resorbable radiopaque marker and method of locating such within a body
US5676146A (en) * 1996-09-13 1997-10-14 Osteotech, Inc. Surgical implant containing a resorbable radiopaque marker and method of locating such within a body
US6316522B1 (en) * 1997-08-18 2001-11-13 Scimed Life Systems, Inc. Bioresorbable hydrogel compositions for implantable prostheses
US6231615B1 (en) * 1997-10-14 2001-05-15 Parallax Medical, Inc. Enhanced visibility materials for implantation in hard tissue
US6214315B1 (en) * 1997-11-03 2001-04-10 Micro Therapeutics Inc Radioactive embolizing compositions
US6562317B2 (en) * 1997-11-03 2003-05-13 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6015541A (en) * 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6251418B1 (en) * 1997-12-18 2001-06-26 C.R. Bard, Inc. Systems and methods for local delivery of an agent
US6336904B1 (en) * 1998-04-07 2002-01-08 Pro Duct Health, Inc. Methods and devices for the localization of lesions in solid tissue
US6183497B1 (en) * 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6537193B1 (en) * 1998-06-17 2003-03-25 Scimed Life Systems, Inc. Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US6270464B1 (en) * 1998-06-22 2001-08-07 Artemis Medical, Inc. Biopsy localization method and device
US6356782B1 (en) * 1998-12-24 2002-03-12 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US20020035324A1 (en) * 1998-12-24 2002-03-21 Sirimanne D. Laksen Subcutaneous cavity marking device and method
US6371904B1 (en) * 1998-12-24 2002-04-16 Vivant Medical, Inc. Subcutaneous cavity marking device and method
US6427081B1 (en) * 1999-02-02 2002-07-30 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US20020188196A1 (en) * 1999-02-02 2002-12-12 Burbank Fred H. Cavity-filling biopsy site markers
US6347241B2 (en) * 1999-02-02 2002-02-12 Senorx, Inc. Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it
US6161034A (en) * 1999-02-02 2000-12-12 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6567689B2 (en) * 1999-02-02 2003-05-20 Senorx, Inc. Methods and chemical preparations for time-limited marking of biopsy sites
US6862470B2 (en) * 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US6662041B2 (en) * 1999-02-02 2003-12-09 Senorx, Inc. Imageable biopsy site marker
US6766186B1 (en) * 1999-06-16 2004-07-20 C. R. Bard, Inc. Post biospy tissue marker and method of use
US6450937B1 (en) * 1999-12-17 2002-09-17 C. R. Bard, Inc. Needle for implanting brachytherapy seeds
US6350244B1 (en) * 2000-02-21 2002-02-26 Biopsy Sciences, Llc Bioabsorable markers for use in biopsy procedures
US6394965B1 (en) * 2000-08-15 2002-05-28 Carbon Medical Technologies, Inc. Tissue marking using biocompatible microparticles
US20020095205A1 (en) * 2001-01-12 2002-07-18 Edwin Tarun J. Encapsulated radiopaque markers
US20040002650A1 (en) * 2001-06-20 2004-01-01 Evgenia Mandrusov Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US6605047B2 (en) * 2001-09-10 2003-08-12 Vivant Medical, Inc. Biopsy marker delivery system
US20030165478A1 (en) * 2002-02-14 2003-09-04 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US20030233101A1 (en) * 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US20050065453A1 (en) * 2003-02-24 2005-03-24 Senorx, Inc. Biopsy device with selectable tissue receiving aperture orientation and site illumination
US20040213756A1 (en) * 2003-04-15 2004-10-28 Michal Eugene T. Methods and compositions to treat myocardial conditions

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541764B2 (en) 1997-10-10 2013-09-24 Senorx, Inc. Method of utilizing an implant for targeting external beam radiation
US8288745B2 (en) * 1997-10-10 2012-10-16 Senorx, Inc. Method of utilizing an implant for targeting external beam radiation
US20080281388A1 (en) * 1997-10-10 2008-11-13 John Corbitt Method of utilizing an implant for targeting external beam radiation
US8680498B2 (en) 1997-10-10 2014-03-25 Senorx, Inc. Method of utilizing an implant in a human breast
US9649093B2 (en) 1999-02-02 2017-05-16 Senorx, Inc. Cavity-filling biopsy site markers
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US20060084865A1 (en) * 1999-02-02 2006-04-20 Burbank Fred H Imageable biopsy site marker
US9044162B2 (en) 1999-02-02 2015-06-02 Senorx, Inc. Marker delivery device with releasable plug
US20090131825A1 (en) * 1999-02-02 2009-05-21 Senorx, Inc. Imageable biopsy site marker
US9237937B2 (en) 1999-02-02 2016-01-19 Senorx, Inc. Cavity-filling biopsy site markers
US8219182B2 (en) 1999-02-02 2012-07-10 Senorx, Inc. Cavity-filling biopsy site markers
US9861294B2 (en) 1999-02-02 2018-01-09 Senorx, Inc. Marker delivery device with releasable plug
US8965486B2 (en) 1999-02-02 2015-02-24 Senorx, Inc. Cavity filling biopsy site markers
US8626270B2 (en) 1999-02-02 2014-01-07 Senorx, Inc. Cavity-filling biopsy site markers
US7565191B2 (en) 1999-02-02 2009-07-21 Senorx, Inc. Tissue site markers for in vivo imaging
US7792569B2 (en) 1999-02-02 2010-09-07 Senorx, Inc. Cavity-filling biopsy site markers
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US20060036165A1 (en) * 1999-02-02 2006-02-16 Senorx, Inc. Tissue site markers for in vivo imaging
US20100010342A1 (en) * 1999-02-02 2010-01-14 Senorx, Inc. Tissue site markers for in vivo imaging
US9149341B2 (en) 1999-02-02 2015-10-06 Senorx, Inc Deployment of polysaccharide markers for treating a site within a patient
US8224424B2 (en) 1999-02-02 2012-07-17 Senorx, Inc. Tissue site markers for in vivo imaging
US8718745B2 (en) 2000-11-20 2014-05-06 Senorx, Inc. Tissue site markers for in vivo imaging
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US8177792B2 (en) 2002-06-17 2012-05-15 Senorx, Inc. Plugged tip delivery tube for marker placement
US8784433B2 (en) 2002-06-17 2014-07-22 Senorx, Inc. Plugged tip delivery tube for marker placement
US20030233101A1 (en) * 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US20040024333A1 (en) * 2002-07-26 2004-02-05 Stuart Brown Tissue and fluid sampling device
US7740595B2 (en) * 2002-07-26 2010-06-22 Stuart Brown Tissue and fluid sampling device
US9801688B2 (en) 2003-05-23 2017-10-31 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US8880154B2 (en) 2003-05-23 2014-11-04 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US20040236212A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US7970454B2 (en) 2003-05-23 2011-06-28 Senorx, Inc. Marker delivery device with releasable plug
US20040236213A1 (en) * 2003-05-23 2004-11-25 Senorx, Inc. Marker delivery device with releasable plug
US8626269B2 (en) 2003-05-23 2014-01-07 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US20040249278A1 (en) * 2003-06-04 2004-12-09 Krause William R. Biopsy and delivery device
US7169114B2 (en) * 2003-06-04 2007-01-30 Krause William R Biopsy and delivery device
US11849928B2 (en) * 2005-08-10 2023-12-26 C. R. Bard, Inc. Single-insertion, multiple sampling biopsy device usable with various transport systems and integrated markers
US20190321014A1 (en) * 2005-08-10 2019-10-24 C. R. Bard, Inc. Single-insertion, multiple sampling biopsy device usable with various transport systems and integrated markers
US8172770B2 (en) * 2005-09-28 2012-05-08 Suros Surgical Systems, Inc. System and method for minimally invasive disease therapy
US20070123815A1 (en) * 2005-09-28 2007-05-31 Mark Joseph L System and method for minimally invasive disease therapy
US20100287887A1 (en) * 2005-11-17 2010-11-18 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US8544162B2 (en) 2005-11-17 2013-10-01 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US9861450B2 (en) 2005-11-17 2018-01-09 Breast-Med, Inc. Imaging fiducial markers and methods
US7702378B2 (en) 2005-11-17 2010-04-20 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US20070110665A1 (en) * 2005-11-17 2007-05-17 Bolan Patrick J Tissue marker for multimodality radiographic imaging
US8966735B2 (en) 2005-11-17 2015-03-03 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
US11241296B2 (en) 2005-11-17 2022-02-08 Breast-Med, Inc. Imaging fiducial markers and methods
US9241773B2 (en) 2005-11-17 2016-01-26 Breast-Med, Inc. Imaging fiducial markers and methods
US20070118034A1 (en) * 2005-11-22 2007-05-24 Mark Joseph L Surgical site marker delivery system
US8688198B2 (en) * 2005-11-22 2014-04-01 Suros Surgical Sytems, Inc. Surgical site marker delivery system
US20090149746A1 (en) * 2007-11-19 2009-06-11 Rubicor Medical, Inc. Post-biopsy cavity treatment implants and methods
US20090217932A1 (en) * 2008-03-03 2009-09-03 Ethicon Endo-Surgery, Inc. Intraluminal tissue markers
EP2098187A1 (en) * 2008-03-03 2009-09-09 Ethicon Endo-Surgery, Inc. Intraluminal tissue markers
WO2009134340A1 (en) * 2008-04-28 2009-11-05 Corbitt John D Jr System for utilizing an implant for targeting external beam radiation
US11833275B2 (en) 2008-09-23 2023-12-05 Senorx, Inc. Porous bioabsorbable implant
US10786604B2 (en) 2008-09-23 2020-09-29 Senorx, Inc. Porous bioabsorbable implant
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US20100082102A1 (en) * 2008-09-23 2010-04-01 Senorx, Inc. Porous bioabsorbable implant
CN105920676A (en) * 2008-09-23 2016-09-07 塞诺克斯股份有限公司 Porous bioabsorbable implant
CN105920676B (en) * 2008-09-23 2021-06-25 塞诺克斯股份有限公司 Porous bioabsorbable implant
US11359103B2 (en) 2008-11-07 2022-06-14 Viscot Medical, Llc Scrub-resistant ink and methods and apparatus for fabrication and use thereof
US20110077512A1 (en) * 2009-06-16 2011-03-31 Dept. Of Veterans Affairs Biopsy marker composition and method of use
WO2011009077A3 (en) * 2009-07-16 2011-04-28 Trustees Of Boston University Labeled skin lesion biopsy punch and uses thereof
WO2011009077A2 (en) * 2009-07-16 2011-01-20 Trustees Of Boston University Labeled skin lesion biopsy punch and uses thereof
US9198987B2 (en) 2010-06-25 2015-12-01 Kci Licensing, Inc. Systems and methods for imaging sinuses
WO2011163591A1 (en) * 2010-06-25 2011-12-29 Kci Licensing, Inc. Systems and methods for imaging sinuses
US20140171385A1 (en) * 2012-12-14 2014-06-19 Ecd Medical Materials for Short-Term Use in Mammals
US9795455B2 (en) 2014-08-22 2017-10-24 Breast-Med, Inc. Tissue marker for multimodality radiographic imaging
CN110267600A (en) * 2017-02-06 2019-09-20 设备与设计有限责任公司 System, the method and apparatus placed for integrated organization sampling and tissue markers
EP3723618A4 (en) * 2017-12-11 2021-12-15 Hologic, Inc. Ultrasound localization system with advanced biopsy site markers
US11234772B2 (en) 2017-12-11 2022-02-01 Hologic, Inc. Ultrasound localization system with advanced biopsy site markers
US11432883B2 (en) 2017-12-11 2022-09-06 Hologic, Inc. Ultrasound localization system with advanced biopsy site markers
US11464585B2 (en) 2017-12-11 2022-10-11 Hologic, Inc. Ultrasound localization system with advanced biopsy site markers

Also Published As

Publication number Publication date
US7877133B2 (en) 2011-01-25
US20090287078A1 (en) 2009-11-19
WO2004105803A1 (en) 2004-12-09
US10299881B2 (en) 2019-05-28
US8639315B2 (en) 2014-01-28
US8447386B2 (en) 2013-05-21
US20140114186A1 (en) 2014-04-24
US20110092815A1 (en) 2011-04-21
US20130253315A1 (en) 2013-09-26
US10045832B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
US8639315B2 (en) Marker or filler forming fluid
US9861294B2 (en) Marker delivery device with releasable plug
US7970454B2 (en) Marker delivery device with releasable plug
US10172674B2 (en) Intracorporeal marker and marker delivery device
US20050119562A1 (en) Fibrous marker formed of synthetic polymer strands
US20050045192A1 (en) Biopsy localization method and device
US20080039819A1 (en) Marker formed of starch or other suitable polysaccharide
US20090171198A1 (en) Powdered marker
JPH10508504A (en) Method and apparatus for identifying and marking tissue
EP2303174A1 (en) Assembly with hemostatic and radiographically detectable pellets
AU2005302639A1 (en) Fibrous marker formed of synthetic polymer strands

Legal Events

Date Code Title Description
AS Assignment

Owner name: SENORX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURBANK, FRED H.;JONES, MICHAEL L.;LOUW, FRANK;AND OTHERS;REEL/FRAME:014517/0595;SIGNING DATES FROM 20030723 TO 20030728

Owner name: SENORX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BURBANK, FRED H.;JONES, MICHAEL L.;LOUW, FRANK;AND OTHERS;SIGNING DATES FROM 20030723 TO 20030728;REEL/FRAME:014517/0595

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12